

- 
- 26 7. Pathological Anatomy. Faculty of Medicine. University Clinical Hospital & Health<br>27 Research Institute of Santiago de Compostela (IDIS). Travesa da Choupana s/n,<br>28 15706 Santiago de Compostela (Spain).
- 28 15706 Santiago de Compostela (Spain).<br>29
- 
- 29  $\frac{3}{5}$  1570 $\frac{1}{5}$ 30<br>31 son Corresponding author: Monica Martínez Fernández.<br>31 <u>monica martínez@lisgaliciasures</u> Translational Oncology. Gálicia Sur Health<br>32 Research Institute (IIS Gálicia Sur). Hospital Álvaro Cunqueira Estrada de Clara<br>33 Ca <u>monica.martinez@iisgaliciasur.es</u> Translational Oncology. Galicia Sur Health<br>32 Research Institute (IIS Galicia Sur). Hospital Álvaro Cunqueiro. Estrada de Clara<br>33 Campoamor, 341, 36213 Vigo, (Spain). 33 Campoamor, 341, 36213 Vigo, (Spain).<br>33 Campoamor, 341, 36213 Vigo, (Spain).  $\frac{1}{34}$ <br>34 34<br>35
- 

### 36 **Highlights**

37



39 retrotransposition from tumor biology and the comparison of the RetroTest not only offers global LINE-1 retrotransposition rate in real clinical settings. • RetroTest not only offers global LINE-1 retrotransposition ratios but also<br>41 identifies the active LINE-1 source elements.<br>42 • RetroTest elucidates a really early LINE-1 activation in early tumor stages

- 42 RetroTest elucidates a really early LINE-1 active RetroTest elucidates a really early LINE-1 active elements. • RetroTest elucidates a really early LINE-1 activation in early tumor stages<br>43 of Head and Neck Squamous Cell Carcinoma.<br>44 • Whole Genome Analysis and LINE-1 retrotransposition demonstrates
- 43 of Head and Neck Squamous Cell Carcinoma. 44 • Whole Genome Analysis and LINE-1 retrotransposition demonstrates extra of the cancerization in Head and Neck Squamous Cancinoma.<br>47 • LINE-1 retrotransposition favors an earlier and more efficient Head and
- 46 Carcinoma. 11 Neck Squamous Cell Carcinoma diagnosis.<br>49<br>50 **Abstract**
- 

# 50<br>51

37<br>
37<br>
38 • Retr<br>
40 • Retr<br>
41 iden<br>
42 • Retr<br>
44 • Who<br>
45 proc<br>
46 Carc<br>
47 • LINE<br>
48 Neck<br>
49<br>
50 **Abstract**<br>
51 The relevan<br>
52 demonstrat<br>
53 identificatic<br>
54 Also, its cline<br>
55 new meth<br>
56 sequencing<br>
57 tumor **47** • LINE-1 retrotransposition favors an earlier and more efficient Head and<br>
449 • Neck Squamous Cell Carcinoma diagnosis.<br>
449 • Abstract<br>
449 • Charact<br>
449 • The relevant role of LINE-1 (L1) retrotransposition in ca 51 The relev<br>52 demonstr<br>53 identifica<br>54 Also, its c<br>65 new met<br>56 sequencir<br>57 tumor bi<br>58 confirmed<br>59 HNSCC ac<br>60 Our resul<br>61 tumor bi<br>62 retrotran:<br>62 retrotran:<br>63 progressi 51 The relevant role of LINE-1 (L1) retrotransposition in cancer has been recurrently<br>52 demonstrated in recent years. However, their repetitive nature hampers their<br>53 identification and detection, hence remaining inacces 53 identification and detection, hence remaining inaccessible for clinical practice.<br>54 Also, its clinical relevance for cancer patients is still limited. Here, we develop a 54 Also, its clinical relevance for cancer patients is still limited. Here, we develop a<br>55 new method to quantify L1 activation. called RetroTest. based on targeted 55 new method to quantify L1 activation, called RetroTest, based on targeted<br>56 sequencing and a sophisticated bioinformatic pipeline, allowing its application in 56 sequencing and a sophisticated bioinformatic pipeline, allowing its application in<br>57 tumor biopsies. First, we performed the benchmarking of the method and 57 tumor biopsies. First, we performed the benchmarking of the method and<br>58 confirmed its high specificity and reliability. Then we unravel the L1 activation in 58 confirmed its high specificity and reliability. Then, we unravel the L1 activation in<br>59 HNSCC according to a more extensive cohort including all the HNSCC tumor stages. 59 HNSCC according to a more extensive cohort including all the HNSCC tumor stages.<br>60 Our\_results\_confirm\_that\_RetroTest\_is\_remarkably\_efficient\_for\_L1\_detection\_in 50 Our results confirm that RetroTest is remarkably efficient for L1 detection in<br>51 tumor biopsies, reaching a high sensitivity and specificity. In addition, L1 61 tumor biopsies, reaching a high sensitivity and specificity. In addition, L1<br>62 retrotransposition estimation reveals a surprisingly early activation in HNSCC 62 retrotransposition estimation reveals a surprisingly early activation in HNSCC<br>63 progression, contrary to its classical association with advanced tumor stages. This 63 progression, contrary to its classical association with advanced tumor stages. This<br>64 early activation together with the genomic mutational profiling of normal adjacent early activation together with the genomic mutational profiling of normal adjacent

64 early activation together with the genomic mutational profiling of normal adjacent

- 65 tissues supports field cancerization process in this tumor. These results underline<br>66 the importance of estimating L1 retrotransposition in clinical practice towards an<br>67 earlier and more efficient diagnosis in HNSCC.
- 
- 67 earlier and more efficient diagnosis in HNSCC.<br>68  $\frac{68}{100}$  expanded more efficient diagnosis in  $\frac{68}{100}$
- 
- 69<br>70
- 70 Retrotransp 70 Retrotransposition, LINE-1, HNSCC, early diagnosis biomarker, field cancerization

The anti-term of the morning of the morning of the morning than 17% of them truncate<br>
75 Among them, lo<br>
76 represent 17% of them truncate<br>
77 of them truncate<br>
79 epigenetic mech<br>
80 cause [7]. When<br>
81 including cancer<br> 72 Approximately half of human genome is composed of transposable elements (TEs),<br>73 sequences with the ability of moving from one place to another, changing the<br>74 normal structure of the genome in the places where they a 74 normal structure of the genome in the places where they are integrated [1,2].<br>75 Among them, long interspersed nuclear element retrotransposons (LINE-1, L1) 75 Among them, long interspersed nuclear element retrotransposons (LINE-1, L1)<br>76 represent 17% of the entire DNA content with approximately 500.000 copies. most 76 represent 17% of the entire DNA content with approximately 500,000 copies, most<br>77 of them truncated or inactive [3–6]. Specifically, only a small subset of these L1s is 77 of them truncated or inactive [3–6]. Specifically, only a small subset of these L1s is<br>78 active in the human genome, although they stay transcriptionally repressed due to 78 active in the human genome, although they stay transcriptionally repressed due to<br>79 epigenetic mechanisms that prevent the damage that their mobilization would 79 epigenetic mechanisms that prevent the damage that their mobilization would<br>80 cause [7]. When this repression is lost, L1 activation can cause different diseases, 79 equine 179 equine mechanisms that prevents that the cause different diseases, that including cancer [8, 9].  $81$  including cancer  $[8, 9]$ .<br>  $82$  can cause different dif

82 In the framework of the International Consortium of PanCancer (PCAWG), our<br>83 previous analyses shown that somatic L1 insertions represent the major 83 previous analyses shown that somatic L1 insertions represent the major<br>84 restructuring source of cancer genomes, especially important for head-and-neck 84 prestructuring source of cancer genomes, especially important for head-and-neck<br>85 previous analysis represent the major somator somation contribute 85 squamous cell carcinoma (HNSCC)[9]. Aberrant L1 retrotransposition contribute<br>86 to instability within cancer genomes, promoting cancer-driving rearrangements 86 to instability within cancer genomes, promoting cancer-driving rearrangements<br>87 that involve the loss of tumor-suppressor genes and/or the amplification of 87 that involve the loss of tumor-suppressor genes and/or the amplification of<br>88 oncogenes, and favoring some cancer-clones to survive and grow [9]. 88 oncogenes, and favoring some cancer clones to survive and grow [9].<br>89 Despite this demonstrated impact of L1 activation in cancer ;

89 Despite this demonstrated impact of L1 activation in cancer genomes, the<br>90 repetitive nature of L1 elements and their dispersion along the genome hinder 80 Pepetitive nature of L1 elements and their dispersion along the genome hinder<br>191 Dependent of their real activation estimates in tumor samples, preventing its translation into 91 their real activation estimates in tumor samples, preventing its translation into<br>92 patient diagnosis/prognosis. This repetitive nature compels that the majority of 92 patient diagnosis/prognosis. This repetitive nature compels that the majority of<br>93 the available detection methods are based on Whole Genome Sequencing (WGS). 93 the available detection methods are based on Whole Genome Sequencing (WGS),<br>94 unfeasible for most hospitals in their diary practice, or require such good quality unfeasible for most hospitals in their diary practice, or require such good quality  $\mathcal{P}_{\text{max}}$  uncher most hospitals in their diary present) is require such good quality.

96 on small and degraded tissue biopsies.<br>95 DNSCC remanents the second tumor time with highest I.1 estimation [0], but the

97 HNSCC represents the second tumor to all the second tumors of the second tumors of the second tumors of the second tumors of  $\overline{M}$ 97 HNSCC represents the second tumor type with highest L1 activation [9], but the<br>98 clinical implications of L1 retrotransposition are still to be elucidated. Head and<br>99 Neck Cancer is a heterogeneous group of cancers of 99 Neck Cancer is a heterogeneous group of cancers of which more than 90% are<br>100 diagnosed as HNSCC, arising in the stratified epithelium of the oral cavity, pharynx, 100 diagnosed as HNSCC, arising in the stratified epithelium of the oral cavity, pharynx,<br>101 and larynx [10,11]. Tumor development is often triggered by chronic exposure to 101 and larynx [10,11]. Tumor development is often triggered by chronic exposure to<br>102 tobacco or alcohol, while infection with high-risk human papillomaviruses (HPVs) 102 tobacco or alcohol, while infection with high-risk human papillomaviruses (HPVs)<br>103 causes a substantial and rising proportion of these tumors [12]. The lack of 103 touses a substantial and rising proportion of these tumors [12]. The lack of<br>104 the symptoms in the early stages together with the non-existent cancer biomarkers 104 symptoms in the early stages together with the non-existent cancer biomarkers<br>105 lead towards most diagnoses at advanced stages, where the 5-year survival rate is 105 lead towards most diagnoses at advanced stages, where the 5-year survival rate is<br>106 less than 50% [11]. Thus, there is an urgent need to find molecular biomarkers 106 less than 50% [11]. Thus, there is an urgent need to find molecular biomarkers<br>107 that can facilitate an earlier diagnosis and increase patients' life expectancy. 107 that can facilitate an earlier diagnosis and increase patients´life expectancy.<br>108 Based on this, we aimed to unravel the impact of possible L1 activation

108 Based on this, we aimed to unravel the impact of possible L1 activation along<br>109 HNSCC development in a clinical setting. First, we have developed a new efficient 109 HNSCC development in a clinical setting. First, we have developed a new efficient<br>110 method based on L1 transductions, RetroTest, to measure L1 activation even in 110 method based on L1 transductions, RetroTest, to measure L1 activation even in<br>111 biopsies with low DNA inputs. Then. we have evaluated RetroTest sensitivity and 111 biopsies with low DNA inputs. Then, we have evaluated RetroTest sensitivity and<br>112 specificity, demonstrating its high values. Finally, we have assessed L1 112 specificity, demonstrating its high values. Finally, we have assessed L1<br>113 retrotransposition-along-different-tumor-stages, unraveling-for-the-fist-time-a-really 113 retrotransposition along different tumor stages, unraveling for the fist time a really<br>114 early activation in HNSCC and field characterization, arising L1 as a promising 114 early activation in HNSCC and field characterization, arising L1 as a promising<br>115 early diagnostic biomarker. 115 early diagnostic biomarker.<br>115 early diagnostic biomarker.

116  $\frac{115}{2}$ 116<br>117

2.1. Patients and tumor samples<br>
119 2.1. Patients and tumor samples<br>
121 patients of 3 different coh<br>
122 (CHUAC), *Biobanco Vasco*<br>
123 (FPGMX)). The Ethical Com<br>
124 the study (CEIC 2018/567)<br>
125 collected, and charact 2.1. Patients and tumor samples<br>120 Tumor samples and medical records were analyzed in a series of 96 HNSCC<br>121 patients of 3 different cohorts (*Complexo Hospitalario Universitario de A Coruña* 121 patients of 3 different cohorts (Complexo Hospitalario Universitario de A Coruña<br>122 (CHUAC). Biobanco Vasco and Fundación Pública Galeaa de Medicina Xenómica 122 (CHUAC), *Biobanco Vasco* and *Fundación Pública Galega de Medicina Xenómica*<br>123 (FPGMX)). The Ethical Committee for Clinical Research of Santiago-Lugo approved 123 (FPGMX)). The Ethical Committee for Clinical Research of Santiago-Lugo approved<br>124 the study (CEIC 2018/567). Fresh-frozen and FFPE HNSCC tissue bionsies were 124 the study (CEIC 2018/567). Fresh-frozen and FFPE HNSCC tissue biopsies were<br>125 collected, and characteristics of each tumor are specified in Table 1. The 125 collected, and characteristics of each tumor are specified in Table 1. The<br>126 histopathologic status was confirmed by each corresponding Pathology 126 histopathologic status was confirmed by each corresponding Pathology<br>127 Department-following-the-latest-TNM-guidelines. 127 hbepartment following the latest TNM guidelines.<br>128 127 Department following the latest TNM guidelines.

129<br>130

2.2. DNA isolation<br>130 Genomic DNA (gDNA) was extracted from fresh-frozen tissue and formalin-fixed<br>131 paraffin-embedded (FFPE) samples using AllPrep DNA/RNA and AllPrep FFPE 131 paraffin-embedded (FFPE) samples using AllPrep DNA/RNA and AllPrep FFPE<br>132 DNA/RNA Mini Kits (Oiagen), respectively. DNA quantification and integrity were 132 DNA/RNA Mini Kits (Qiagen), respectively. DNA quantification and integrity were<br>133 assessed using Qubit dsDNA BR Assay Kit in Qubit 4.0 (ThermoFisher Scientific) 133 – assessed using Qubit dsDNA BR Assay Kit in Qubit 4.0 (ThermoFisher Scientific)<br>134 – and a 4200 TapeStation svstem (Agilent). 134 and a 4200 TapeStation system (Agilent).<br>135

# 135  $\frac{1}{2}$  and  $\frac{1}{2$ 136<br>137

2.3. RetroTest method: design, library construction and target sequencing<br>137 During L1 transcription, the processing machinery sometimes bypasses the L1<br>138 polyadenylation signal until a second 3' downstream polyadenylat 138 polyadenylation signal until a second 3' downstream polyadenylation site,<br>139 mobilizing unique sequences downstream of the element in a process called *L1 3'* 139 mobilizing unique sequences downstream of the element in a process called *L13'*<br>140 *transduction*. This process has been reported to occur in around 10% of the L1 140 *transduction*. This process has been reported to occur in around 10% of the L1<br>141 mobilizations [7] and can be used as an indirect measurement of real active L1 141 mobilizations [7] and can be used as an indirect measurement of real active L1<br>142 elements. Accordingly, there are three different types of retrotranspositions: soloelements. Accordingly, there are three different types of retrotranspositions: solo-

 $\frac{3}{4}$ 

143 L1 (TD0), when a partial or complete L1 is retrotransposed; partnered<br>144 transductions (TD1), in which a L1 and downstream unique sequence are<br>145 retrotransposed; and orphan transductions (TD2), in which only the uni 145 retrotransposed; and orphan transductions (TD2), in which only the unique<br>146 sequence downstream of the active L1 is mobilized without the associated L1 [7]. 146 sequence downstream of the active L1 is mobilized without the associated L1 [7].<br>147 RetroTest is based on targeted sequencing, where the capture probes are designed 147 RetroTest is based on targeted sequencing, where the capture probes are designed<br>148 against the unique sequence downstream of the 124 L1 full-length competent 148 against the unique sequence downstream of the 124 L1 full-length competent<br>149 elements previously described [7] using SureSelect design from Agilent. RetroTest 149 elements previously described [7] using SureSelect design from Agilent. RetroTest<br>150 identifies L1 TD2 orphan insertions through the detection of discordant reads and 150 identifies L1 TD2 orphan insertions through the detection of discordant reads and<br>151 clipped reads. The main idea behind the method is that discordant read pairs, 151 clipped reads. The main idea behind the method is that discordant read pairs,<br>152 where one of the mates is mapped to a L1 3' downstream sequence while the other 152 where one of the mates is mapped to a L1 3' downstream sequence while the other<br>153 is mapped to the insertion target sequence, support an insertion. In addition, 153 is mapped to the insertion target sequence, support an insertion. In addition,<br>154 – clipped reads, mapped to the target sequence but containing a discordant extreme 154 clipped reads, mapped to the target sequence but containing a discordant extreme<br>155 blatting to a L1 3' downstream sequence, are detected to identify the breakpoint of 155 blatting to a L1 3' downstream sequence, are detected to identify the breakpoint of<br>156 the insertion (Fig. 1A). Here, a minimum size of 2 reads per cluster and a minimum 156 the insertion (Fig. 1A). Here, a minimum size of 2 reads per cluster and a minimum<br>157 of 4 supporting reads was specified to call a L1 insertion (Additional file 1). 157 of 4 supporting reads was specified to call a L1 insertion (Additional file 1).<br>158 Target libraries were constructed with SureSelect Target Enrichment Sys

158 – Target libraries were constructed with SureSelect Target Enrichment System for<br>159 – Illumina Paired-End Multiplexed Sequencing (Agilent). 100 ng of gDNA from each 159 Illumina Paired-End Multiplexed Sequencing (Agilent). 100 ng of gDNA from each<br>160 sample were sheared using a Covaris M220 Focused-Ultrasonicator (Covaris) and 160 sample were sheared using a Covaris M220 Focused-Ultrasonicator (Covaris) and<br>161 libraries and capture with targeted RNA baits were performed. The multiplexed 161 libraries and capture with targeted RNA baits were performed. The multiplexed<br>162 samples were sequenced with Illumina 150bp paired-end. 162 samples were sequenced with Illumina 150bp paired-end.<br>163 Sequencing reads were mapped to the hg19 reference

163 Sequencing reads were mapped to the hg19 reference genome by Burrows-<br>164 Wheeler Aligner BWA-mem [13]. Samtools [14] was used to sort the aligned reads 165 September 163 September 1930 reads were made to the head of the head to the head of the head of the head o<br>The head to the head of th 165 and to index the obtained bam file, applying Bammarkduplicates2 from Picard<br>166 Wheeler War War War aligned reads 166 tools [15] to mark duplicated reads.<br>267 167  $\frac{1}{\sqrt{15}}$  to  $\frac{1}{\sqrt{15}}$  to matrix duplicated reads.

2.4. RetroTest benchmarking<br>169 We generated simulated paired-end read datasets using ART [16] and several<br>170 commands from MEIGA-MEIsimulator, an in-house bioinformatic tool (Additional 170 commands from MEIGA-MEIsimulator, an in-house bioinformatic tool (Additional<br>171 file 1). 171 file 1).<br>172 communication, and the Meisimulator, and in-house biological (Additional Additional Additional Additional

172 To mimic the capture process, we selected read pairs with at least one of the mates<br>173 mapping on a given set of target regions with Picard FilterSamReads v2.18.14 [15]. 173 — mapping on a given set of target regions with Picard FilterSamReads v2.18.14 [15].<br>174 — We used the resulting bam files to assess sensitivity and specificity under different 174 We used the resulting bam files to assess sensitivity and specificity under different<br>175 — conditions. To test how our method performs with subclonal events, we simulated 175 — conditions. To test how our method performs with subclonal events, we simulated<br>176 — transductions at different VAFs (10%, 20%, 40% and 50%). We also studied how 176 transductions at different VAFs (10%, 20%, 40% and 50%). We also studied how<br>177 coverage affects the detection power of our algorithm. Using Picard 177 coverage affects the detection power of our algorithm. Using Picard<br>178 DownSampleSam.v2.18.14 [15], we subsampled reads-from-a-150x-simulation-at 178 DownSampleSam v2.18.14 [15], we subsampled reads from a 150x simulation at<br>179 50% VAF under different sequencing depths (15x, 30x, 60x, 90x, 120x and 150x). 179 50% VAF under different sequencing depths (15x, 30x, 60x, 90x, 120x and 150x).<br>180 We compared RetroTest performance with Transposon Finder in Cancer (TraFiC

180 We compared RetroTest performance with Transposon Finder in Cancer (TraFiC),<br>181 used previously to explore somatic retrotransposition in PCAWG [7]. Both were 181 used previously to explore somatic retrotransposition in PCAWG [7]. Both were<br>182 wsed to call the simulated events. Precision was calculated dividing the number of 182 used to call the simulated events. Precision was calculated dividing the number of<br>183 true positive calls by the number of total calls performed by the method. Recall 183 true positive calls by the number of total calls performed by the method. Recall<br>184 was calculated dividing the number of true positive calls by the number of total 184 trues calculated dividing the number of true positive calls by the number of total<br>185 true simulated events. True positives, False positives and False negatives were 185 simulated events. True positives, False positives and False negatives were<br>186 identified by intersecting the coordinates of simulated events with the coordinates 185 simulated events. True positives, False positives and False negatives were 187 of the calls using BEDTools intersect [17]. To compare RetroTest and TraFiC<br>188 results, Venn diagrams with the insertions detected by each method were plotted 188 results, Venn diagrams with the insertions detected by each method were plotted<br>189 by using vennDiagram R package. 189 by using venn Diagram R package.<br>189 189 by using v*ennDiagram* R package.<br>190

191 2. 5. Whole Genome Sequencing and determination of mutation profile.

192 To obtain WGS data, DNA was sent to an external service (Macrogen). Truseq Nano<br>193 DNA Libraries (350bp) were constructed and sequenced in a NovaSeq6000<br>194 Illumina platform (150bp paired-end). For a detailed explana 194 - Illumina platform (150bp paired-end). For a detailed explanation see Additional<br>195 - File 1. 195 File 1. For a detailed explanation see Additional explanation see Additional explanation see Addition see Additional explanation see Addition see Addition see Addition see Additional explanation see Additional explana

196<br>107 = 26 St

196<br>197<br>198 2.6. *Statistical analyses*<br>198 The association between L1 transduction rate (corrected by coverage) and patient<br>199 clinical features was assessed by multiple linear regressions. Wilcoxon or Fisher 199 clinical features was assessed by multiple linear regressions. Wilcoxon or Fisher<br>200 test, depending on sample size, were applied to compare the differences in mean 199 test, depending on sample size, were applied to compare the differences in mean<br>1991 - values for clinical variables. Overall survival (OS), progression free survival (PFS) 201 values for clinical variables. Overall survival (OS), progression free survival (PFS)<br>202 and survival probability analyses were performed with the *survminer* and *survival* 202 and survival probability analyses were performed with the *survminer* and *survival*<br>203 R packages, using log-rank test to compare different groups. The association 203 R packages, using log-rank test to compare different groups. The association<br>204 between survival and clinical variables was evaluated by Cox regression. 204 between survival and clinical variables was evaluated by Cox regression.<br>205 205<br>206 between survival and clinical variables was evaluated by Cox regression.

206<br>207

206 2.7. Enrichment analysis 207 All enrichment analyses were performed using *enrichR* R package [18]. The<br>208 complete list of pathways databases can be found in Additional File 1.<br>200

 $\frac{1}{209}$  complete list of pathways databases can be found in Additional Fieldings can be found in Additiona 209<br>210

### 211 3. Results

212 3.1. RetroTu<br>
212 3.1. RetroTu<br>
213 During L1<br>
214 L1 mobiliz<br>
215 element. F<br>
216 transduced<br>
217 barcodes<br>
218 caused by<br>
219 focused Re<br>
220 regions for<br>
221 frequently<br>
222 measure of<br>
224 correlation<br>
225 previous 212 3.1. RetroTest Benchmarking<br>213 During L1 transcription, transductions are reported to occur in around 10% of the<br>214 L1 mobilizations [7], moving also unique sequences downstream of the source 214 L1 mobilizations [7], moving also unique sequences downstream of the source<br>215 element. RetroTest is designed to capture these mobilized and downstream-215 element. RetroTest is designed to capture these mobilized and downstream-<br>216 transduced unique sequences from orphan transductions (TD2) and use them as  $215$  element. RetroTest is designed to capture these mobilized and downstream-217 barcodes (Fig. 1A). These barcodes can identify unequivocally the insertions  $\frac{210}{2}$  and use them as  $\frac{210}{2}$ 217 barcodes (Fig. 1A). These barcodes can identify unequivocally the insertions<br>218 caused by these 124 L1 source elements active in cancer [7,9]. With this aim, we<br>219 focused RetroTest probe design on the first 5000 nuc 219 focused RetroTest probe design on the first 5000 nucleotides adjacent to the L1 3'<br>220 Fregions for each of the 124 L1 source elements, since these are the regions most 220 fregions for each of the 124 L1 source elements, since these are the regions most<br>221 frequently transduced [7]. Since RetroTest uses transductions as an indirect 221 frequently transduced [7]. Since RetroTest uses transductions as an indirect<br>222 measure of real L1 activation, we first compared L1 activation v*ersus* TD2 using the 222 measure of real L1 activation, we first compared L1 activation *versus* TD2 using the<br>223 whole PCAWG data. In this way, we confirmed a high and statistically significant 223 whole PCAWG data. In this way, we confirmed a high and statistically significant<br>224 correlation between both events (r=0.88, p=2.2e<sup>-16</sup>), and a relation of 1:10 as 224 whole PCAWG data. In this way, we confirm a high and statistically significant<br>224 whole probability of the definition of  $1.10$  as 224 a correlation between both events (r=0.88, p=2.2e<sup>-16</sup>), and a relation of 1:10 as<br>225 a previously described (Fig. 1B).<br>226 a Nart are entimized the lab untegal fan heth FFPE and fresh fresen tieruse and

previously described (Fig. 1B).<br>226 Next, we optimized the lab protocol for both FFPE and fresh-frozen tissues and<br>227 developed an associated bioinformatic pipeline. We evaluated the performance 227 developed an associated bioinformatic pipeline. We evaluated the performance<br>228 and accuracy of RetroTest in detecting L1 activation by generating an artificial 228 and accuracy of RetroTest in detecting L1 activation by generating an artificial<br>229 cancer genome. In this genome, we have randomly distributed a total of 2480 L1 229 cancer genome. In this genome, we have randomly distributed a total of 2480 L1<br>230 transductions. Using simulations, we assessed the performance of RetroTest for 230 transductions. Using simulations, we assessed the performance of RetroTest for<br>231 different sequencing depth: 15x, 30x, 60x, 90x, 120x and 150x. RetroTest obtained 231 different sequencing depth: 15x, 30x, 60x, 90x, 120x and 150x. RetroTest obtained<br>232 a precision around 0.99 in all cases and a recall around 0.96 (Fig. 1C). We also 232 a precision around 0.99 in all cases and a recall around 0.96 (Fig. 1C). We also<br>233 evaluated the variation of the performance depending on the variant allele 233 evaluated the variation of the performance depending on the variant allele<br>234 frequency (VAF) of the integrations, precisely for the following VAFs: 10%, 20%, 234 frequency (VAF) of the integrations, precisely for the following VAFs: 10%, 20%,<br>235 40% and 50%. In this case, RetroTest obtained a precision around 1, decreasing 40% and 50%. In this case, RetroTest obtained a precision around 1, decreasing 235 40% and 50%. In this case, RetroTest obtained a precision around 1, decreasing

237 For the lower Variation and a recall range of the lower Variation of the substituting as increasing the<br>220 Theory we seems and Datus Test and the sleepisel TraFiC weed for WCS in DCAWC

238 Then, we com 238 Then, we compared RetroTest and the classical TraFiC, used for WGS in PCAWG<br>239 [7]. As TraFiC is designed to work only with standard WGS 30x data, we compared<br>240 the analysis varving exclusively the VAFs. TraFiC 240 the analysis varying exclusively the VAFs. TraFiC precision ranged from 0.99 to<br>241 0.88 and recall ranged from 0.11 to 0.87 as VAF increased (although the maximum 241 0.88 and recall ranged from 0.11 to 0.87 as VAF increased (although the maximum<br>242 recall was obtained for VAFs of 40%, being 0.87) (Fig. 1E) (Additional File 2: Table 242 recall was obtained for VAFs of 40%, being 0.87) (Fig. 1E) (Additional File 2: Table<br>243 S1). We compared the performance of both methods by intersecting both calls in 243 S1). We compared the performance of both methods by intersecting both calls in<br>244 the mock tumor genome. Using a VAF of 50%, most of the variants were called by 244 the mock tumor genome. Using a VAF of 50%, most of the variants were called by<br>245 both methods, concretely 2216 variants, while RetroTest exclusively called 167, 245 both methods, concretely 2216 variants, while RetroTest exclusively called 167,<br>246 and TraFiC 33 private events, most of them resulting in false positives according to 246 and TraFiC 33 private events, most of them resulting in false positives according to<br>247 IGV (Fig. 1F). 247 and TraFic 33 private events, most of them resulting in fact, positive according to the<br>247 and CF 349

 $248$ <br>249  $2211$ . 15 248<br>249<br>250

3.2. L1 activation in HNSCC<br>250 Once confirmed the accuracy and precision of RetroTest, we decided to apply it to<br>251 a more extensive HNSCC cohort, composed of 96 tumors along the tumor stages, 251 – a more extensive HNSCC cohort, composed of 96 tumors along the tumor stages,<br>252 – from T1 to T4 (Table 1). We detected L1 activation in 75% of the patients (Fig. 2A). 252 from T1 to T4 (Table 1). We detected L1 activation in 75% of the patients (Fig. 2A),<br>253 out of which 48.6% showed high activity (beyond the median) (Table 2). When the 253 out of which 48.6% showed high activity (beyond the median) (Table 2). When the<br>254 activation was studied along the different tumor stages of the disease, advanced 254 activation was studied along the different tumor stages of the disease, advanced<br>255 disease (T3-T4) showed statistically higher L1 activation compared with early 255 disease (T3-T4) showed statistically higher L1 activation compared with early<br>256 stages (T1-T2) (p=0.0072) (Fig. 2B). Following tumor staging, L1 activation was 256 stages (T1-T2) (p=0.0072) (Fig. 2B). Following tumor staging, L1 activation was<br>257 detected in 62.5% of T1 tumors, 63.1% of T2 tumors, 94.4% of T3 tumors, and 257 detected in 62.5% of T1 tumors, 63.1% of T2 tumors, 94.4% of T3 tumors, and<br>258  $-73.5\%$  of the tumors in T4 (Table 2). The detection of L1 activation in all the tumor 258 73.5% of the tumors in T4 (Table 2). The detection of L1 activation in all the tumor<br>259 stages among the different patients, even in the first stage of the disease (T1), 259 stages among the different patients, even in the first stage of the disease (T1),<br>260 supports an early L1 activation during tumor progression. supports an early L1 activation during tumor progression. 260 supports an early L1 activation during tumor progression.

261 Then, we analyzed L1 activation considering different patients' clinical<br>262 characteristics, finding no statistically significant association between the L1<br>263 activation and alcohol consumption ( $p=0.14$ ) or sex (263 activation and alcohol consumption ( $p=0.14$ ) or sex ( $p=0.055$ ). Interestingly,<br>264 smoker patients showed statistically significantly higher L1 activity than non-264 smoker patients showed statistically significantly higher L1 activity than non-<br>265 smokers (p=0.0015) (Fig. 2C). We did not find an association between L1  $266$  so the time  $\frac{1}{2}$  smoker patient statistically higher L1 activity than  $\frac{1}{2}$  activity than  $\frac{1}{2}$  activity than  $\frac{1}{2}$ 265 smokers (p=0.0015) (Fig. 2C). We did not find an association between L1<br>266 activation and survival probability (p=0.59 active vs. inactive, p= 0.49 high vs. low 266 activation and survival probability ( $p=0.59$  active vs. inactive,  $p=0.49$  high vs. low<br>267 ate) (Additional File 3: Fig. S1), although when considering those T1 patients who<br>268 have L1 already active at early stage 268 have L1 already active at early stages, Kaplan-Meier curve showed that they tend<br>269 to have a lower survival probability, not being statistically significant (p=0.43) 269 to have a lower survival probability, not being statistically significant (p=0.43)<br>270 (Fis. 3D) 269 to have a lower survival probability, not being statistically significant (p=0.43)<br>270 (Fig. 2D).<br>271 Finally in addition to lacalizing the magitian of each transduction. Petro Tast are:

270 (Fig. 2D).<br>271 Finally, in addition to localizing the position of each transduction, RetroTest can<br>272 also identify the source L1 element that has been mobilized. Thus, we have 272 also identify the source L1 element that has been mobilized. Thus, we have<br>273 detected L1 transductions in 23 genes throughout 27 patients. As shown in Fig. 2E, 273 detected L1 transductions in 23 genes throughout 27 patients. As shown in Fig. 2E,<br>274 — most of these insertions are caused by a few source elements that resulted very 274 most of these insertions are caused by a few source elements that resulted very<br>275 active in HNSCC, especially the 22q12.1. 275 active in HNSCC, especially the 22q12.1.<br>275 active in HNSCC, especially the 22q12.1.

276<br>277<br>278

# 275 and the 22  $\frac{1}{2}$  ( $\frac{2}{3}$  and  $\frac{2}{3}$  and

3.3. HNSCC mutation profile and L1 activation<br>278 To further characterize the molecular profile of L1 activation in our HNSCC cohort,<br>279 we obtained WGS data from 19 tumor samples from patients measured 279 we obtained WGS data from 19 tumor samples from patients measured by<br>280 RetroTest. To detect only somatic variation, their corresponding paired-normal 280 RetroTest. To detect only somatic variation, their corresponding paired-normal<br>281 samples were included as germline control. We detected a median of 40 single 281 samples were included as germline control. We detected a median of 40 single<br>282 nucleotide variants (SNVs) and INDELs, identifying a total of 1012 somatic variants 282 nucleotide variants (SNVs) and INDELs, identifying a total of 1012 somatic variants<br>283 throughout the cohort, affecting 918 genes (Additional File 2: Table S2). As shown 283 throughout the cohort, affecting 918 genes (Additional File 2: Table S2). As shown<br>284 in Fig. 3A, we did not detect a correlation between L1 activation and the general 284 in Fig. 3A, we did not detect a correlation between L1 activation and the general<br>285 tumor mutation burden (TMB). Our results showed that the most frequently tumor mutation burden (TMB). Our results showed that the most frequently  $\frac{2}{3}$ 

mutated gene was *TP53* (36.8%), followed by *NOTCH1* (26.3%), *MT-ND5* (26.3%),<br>287 FAT1, and GRIN2A (21.1%). Interestingly, we found that most of the patients with<br>288 TP53 mutations showed also high L1 activity (71.4%). 288 *TP53* mutations showed also high L1 activity (71.4%). In fact, when we compared<br>289 the L1 activation with the *TP53* mutation, we found a clear association (p=0.056) 289 the L1 activation with the *TP53* mutation, we found a clear association ( $p=0.056$ ). <br>290 (Fig. 3B). Enrichment analyses with the mutated genes showed involved kev 290 (Fig. 3B). Enrichment analyses with the mutated genes showed involved key<br>291 processes for cancer progression such as *Notch signaling, TGFß signaling,* and 291 (processes for cancer progression such as *Notch signaling, TGFß signaling,* and<br>292 (again *p53 activity reaulation* (Fig. 3C) (Additional File 2: Table S3). CHEA analysis 292 again *p53 activity regulation* (Fig. 3C) (Additional File 2: Table S3). CHEA analysis<br>293 revealed the alteration of transcription factors related to epigenetic mechanisms 293 revealed the alteration of transcription factors related to epigenetic mechanisms<br>294 including Polycomb members (*EZH2, SUZ12*) (Fig. 3D) (Additional File 2: Table S4). 294 including Polycomb members (*EZH2, SUZ12*) (Fig. 3D) (Additional File 2: Table S4).<br>205 294 including Polycomb members (*EZH2, SUZ12*) (Fig. 3D) (Additional File 2: Table S4).<br>295<br>20*6 24 Prefilis converted interest times to the UNSSC tumes (MA*T).

295<br>296<br>297

296 3.4. Profiling normal adjacent tissues to the HNSCC tumor (NAT)<br>297 To further understand the early HNSCC features, we decided to evaluate a possible<br>298 field cancerization process, in which the normal cell population 298 field cancerization process, in which the normal cell population is replaced by<br>299 cancer-primed cells, without anatomical or morphological changes, but being 299 field cancer-primed cells, without anatomical or morphological changes, but being<br>1988 field population at the normal cell population is replaced the available normal is also already premalignant at molecular level. To 200 already premalignant at molecular level. To this, we analyzed the available normal<br>201 samples obtained from adjacent tissues to the tumor and the peripheral blood 301 - samples obtained from adjacent tissues to the tumor and the peripheral blood<br>302 - mononuclear cells (PBMCs), used as germline control (Fig. 4A). We detected a total 302 mononuclear cells (PBMCs), used as germline control (Fig. 4A). We detected a total<br>303 of 25 high impact and/or possibly pathogenic somatic variants affecting the NAT 303 of 25 high impact and/or possibly pathogenic somatic variants affecting the NAT<br>304 (Additional File 2: Table S5). Most of these specific mutations (n=20; 80%) were 304 (Additional File 2: Table S5). Most of these specific mutations (n=20; 80%) were<br>305 exclusive from NAT tissue, including those affecting key genes such as *NOTCH1* 305 exclusive from NAT tissue, including those affecting key genes such as *NOTCH1*<br>306 (the most mutated gene), *FAT1* or *PPARD*; while 20% were shared between NAT 305 exclusive from NAT tissue, including those affecting key genes such as *NOTCH1*<br>306 (the most mutated gene), *FAT1* or *PPARD*; while 20% were shared between NAT<br>207 306 (the most mutated gene), *FAT1* or *PPARD*; while 20% were shared between NAT<br>307 and tumor tissue, affecting genes such as *CDKN2A*.<br>209 Ta sharidate substhan J.1 further suments field association are conj

and tumor tissue, affecting genes such as *CDKN2A*.<br>308 To elucidate whether L1 further supports field cancerization, we evaluated the<br>309 NAT of a total of 9 patients by RetroTest. We compared the L1 elements act 309 NAT of a total of 9 patients by RetroTest. We compared the L1 elements active in<br>310 the tumor, in the NAT, and in their corresponding paired germline. In this way, we the tumor, in the NAT, and in their corresponding paired germline. In this way, we 310 the tumor, in the NAT, and in their corresponding paired germline. In this way, we

311 could confirm that most of the L1 activation was present only in the tumor, 5<br>312 insertions resulted germline, and 1 element appeared active and shared by tumor<br>313 and NAT. Surprisingly, 4 insertions appeared exclusi 313 and NAT. Surprisingly, 4 insertions appeared exclusively in NAT (Fig. 4B). Thus, we<br>314 could confirm field cancerization and demonstrate that L1 is already active in NAT. 314 — could confirm field cancerization and demonstrate that L1 is already active in NAT,<br>315 — supporting once again its early activation in HNSCC. 315 supporting once again its early activation in HNSCC.<br>316 316<br>316<br>347 de Dieuveleu

## 317<br>318

318 Since the recent<br>319 been evaluated<br>320 evaluating L1<br>321 most of L1 ge<br>322 present impor<br>323 routine can b<br>324 technologies b<br>325 such as RC-sec<br>326 besides only c<br>327 starting genon<br>328 approaches ar<br>329 measure (Tra 318 Since the recently demonstrated high impact of L1 in cancer genomes [7,9], L1 has<br>319 been evaluated as a cancer biomarker in different studies assessing its activity by<br>320 evaluating L1 methylation, RNA expression, o 320 evaluating L1 methylation, RNA expression, or protein levels [19–22]. However,<br>321 most of L1 genome sequences are truncated and not functional, so results can 321 evaluat of L1 genome sequences are truncated and not functional, so results can<br>322 eresent important biases in their L1 estimations, while its translation into clinical 322 present important biases in their L1 estimations, while its translation into clinical<br>323 routine can be challenging due to RNA/protein instability. Previous proposed 323 proutine can be challenging due to RNA/protein instability. Previous proposed<br>324 technologies based on DNA full-length L1 retrotransposon capture sequencing. 324 technologies based on DNA full-length L1 retrotransposon capture sequencing,<br>325 such as RC-seq [23], present the associated possible bias of the real L1 activation, 325 such as RC-seq [23], present the associated possible bias of the real L1 activation,<br>326 besides only offer global L1 estimates, and important DNA requirements (2.5µg 326 besides only offer global L1 estimates, and important DNA requirements (2.5µg<br>327 starting genomic DNA), unaffordable for clinical practice. The most recent 327 starting genomic DNA), unaffordable for clinical practice. The most recent<br>328 approaches are based on the identification of L1 insertions as real L1 activation 328 approaches are based on the identification of L1 insertions as real L1 activation<br>329 measure (TraFiC [7], xTea [24], MELT [25] and Mobster [26]). They use Whole 329 measure (TraFiC [7], xTea [24], MELT [25] and Mobster [26]). They use Whole<br>330 Genome or Whole Exome Sequencing from Illumina pair-end short reads, 330 Genome or Whole Exome Sequencing from Illumina pair-end short reads,<br>331 mevertheless, short reads hamper the detection of transposable elements 331 nevertheless, short reads hamper the detection of transposable elements<br>332 insertions in highly repetitive or complex rearrangement regions. Additionally, 332 insertions in highly repetitive or complex rearrangement regions. Additionally,<br>333 these high throughput approaches are not affordable for most of the hospitals. 333 these high throughput approaches are not affordable for most of the hospitals.<br>334 More recently, long reads sequencing has arisen as a new possibility (xTea [24], 334 More recently, long reads sequencing has arisen as a new possibility (xTea [24],<br>335 PALMER [27]), but again their requirements of huge amounts of high-quality DNA PALMER [27]), but again their requirements of huge amounts of high-quality DNA  $\frac{3}{3}$  Palmer requirements of huge and  $\frac{3}{2}$  Palmer requirements of  $\frac{3}{2}$  Palm

336 remain unaffordable for biopsies mainly composed of small samples and<br>337 fragmented DNA. Thus, incorporating L1 activation into the clinical practice<br>338 requires new methods supported by standardization and rigorous 338 fraguires new methods supported by standardization and rigorous validation to<br>339 demonstrate its utility. 339 demonstrate its utility.<br>339 demonstrate its utility.<br>340 U

340 Here, we present RetroTest: a new method to detect real L1 activation in clinical<br>341 samples with low DNA input requirements. both from fresh/frozen or FFPE 341 samples with low DNA input requirements, both from fresh/frozen or FFPE<br>342 bionsies. Its novelty and nower lie in the targeted detection of active source L1 342 biopsies. Its novelty and power lie in the targeted detection of active source L1<br>343 elements, which showed a highly and direct statistical correlation with total L1 343 elements, which showed a highly and direct statistical correlation with total L1<br>344 activity (as demonstrated by our data) in a more cost-effective than previously 344 activity (as demonstrated by our data) in a more cost-effective than previously<br>345 proposed approaches. Our method not only offers global L1 estimates but also 345 proposed approaches. Our method not only offers global L1 estimates but also<br>346 identifies the L1 elements active in each real sample. Our benchmarking supports 346 identifies the L1 elements active in each real sample. Our benchmarking supports<br>347 the high precision (1) and recall of RetroTest (0.81-0.96), improving according to 347 the high precision (1) and recall of RetroTest (0.81-0.96), improving according to<br>348 coverage, even reaching the possibility of detecting subclonal insertions. The high 348 the coverage, even reaching the possibility of detecting subclonal insertions. The high<br>349 the coincidence in the variants called by TraFic and RetroTest, in both simulations and 349 coincidence in the variants called by TraFic and RetroTest, in both simulations and<br>350 real-world data, supports the high potential for this new methodology. 350 real-world data, supports the high potential for this new methodology.<br>351 L1 somatic retrotransposition was previously demonstrated as the s

351 L1 somatic retrotransposition was previously demonstrated as the second most<br>352 frequent tvpe of structural variants among HNSCC genomes [9]. Accordingly. our 352 frequent type of structural variants among HNSCC genomes [9]. Accordingly, our<br>353 results demonstrate that most HNSCC patients (75%) present L1 activation, even 353 fresults demonstrate that most HNSCC patients (75%) present L1 activation, even<br>354 frear half of them with high levels (49%). The activation was higher in late stages. 354 rear half of them with high levels (49%). The activation was higher in late stages,<br>355 as found in Barret's esophagus, where lower L1 activity was detected in the early 355 as found in Barret's esophagus, where lower L1 activity was detected in the early<br>356 stages increasing with cancer progression [28]. Interestingly, we found a 356 stages increasing with cancer progression [28]. Interestingly, we found a<br>357 surprisingly early activation already in the first stages of HNSCC with activation of 357 surprisingly early activation already in the first stages of HNSCC, with activation of<br>358 L1 in 62-63% of the T1 patients. These data pointed towards L1 activation as an 358 L1 in 62-63% of the T1 patients. These data pointed towards L1 activation as an<br>359 early event in the configuration of HNSCC genomes and, thus, in the development early event in the configuration of HNSCC genomes and, thus, in the development 359 early event in the configuration of HNSCC genomes and, thus, in the development

361 of the disease in the y disease stage. If patients with L1 activity and amolting hebits. Beginning

362 We found a 362 We found an association between high L1 activity and smoking habits. Previous<br>363 studies had reported higher hypomethylation rates of L1 in smokers [29], even in<br>364 non-cancerous epithelial tissues [30]. 364 — non-cancerous epithelial tissues [30]. Considering that around 75% of HNSCC are<br>365 — associated with tobacco [31], this mechanism could be responsible for the high L1 365 associated with tobacco [31], this mechanism could be responsible for the high L1<br>366 activity levels in HNSCC. since methvlation is one of the best-demonstrated 366 activity levels in HNSCC, since methylation is one of the best-demonstrated<br>367 mechanisms preventing L1 reactivation [7,32]. In fact, L1 hypomethylation has 367 mechanisms preventing L1 reactivation [7,32]. In fact, L1 hypomethylation has<br>368 been associated with worse prognosis in HNSCC, including a higher risk of relapse 368 been associated with worse prognosis in HNSCC, including a higher risk of relapse<br>369 [33–35]. This hypomethylation has been found as an early event in CRC, gastric 369 [33–35]. This hypomethylation has been found as an early event in CRC, gastric<br>370 and oral cancer [36–39]. Interestingly, it was reported that L1 methylation levels 370 and oral cancer [36–39]. Interestingly, it was reported that L1 methylation levels<br>371 were significantly lower in oral premalignant lesions of patients who then 371 were significantly lower in oral premalignant lesions of patients who then<br>372 developed.oral.cancer.[39].  $372$  developed oral cancer [39].

373 The source element L1 most active in our cohort was that at 22q12.1, coincident<br>374 with our previous results [7, 10]. This L1 is located antisense to an intron of the 374 with our previous results [7, 10]. This L1 is located antisense to an intron of the<br>375 TTC28 gene and has been also recently identified as the intact LINE-1 mRNA most 375 TTC28 gene and has been also recently identified as the intact LINE-1 mRNA most<br>376 highly expressed in breast, ovarian and colon cancer [40], and the L1 element 376 highly expressed in breast, ovarian and colon cancer [40], and the L1 element<br>377 accounting for most transductions in colorrectal cancer [33], supporting the same 377 accounting for most transductions in colorrectal cancer [33], supporting the same<br>378 hottest activity in HNSCC. 377 accounting for most transductions in colorrectal cancer [33], supporting the same

379 Our WGS analyses confirmed no correlation between L1 activity and TMB, but an<br>380 association between *TP53* mutation and L1 activation, in line with previous studies 380 – association between *TP53* mutation and L1 activation, in line with previous studies<br>381 – suggesting that *TP53* can repress L1 mobilization [9,40–43]. We also identified an 381 - suggesting that *TP53* can repress L1 mobilization [9,40–43]. We also identified an<br>382 - important epigenetic regulation among the transcription factors strongly 382 important epigenetic regulation among the transcription factors strongly<br>383 interacting with the mutated genes, specially related to repressive complex 383 interacting with the mutated genes, specially related to repressive complex<br>384 Polycomb Intriguingly, Mangoni et al. have just deciphered that L1 RNAs can act as Polycomb. Intriguingly, Mangoni et al. have just deciphered that L1 RNAs can act as  $\frac{3}{2}$  Polycomb. Intriguingly, Mangoni et al. have just deciphered that L13

385 long non-coding RNAs and directly interact with the Polycomb during brain<br>386 development and evolution [44]. We also reported previously that Polycomb could<br>387 regulate lncRNA *HOTAIR* in bladder cancer [45]. In the 387 regulate lncRNA *HOTAIR* in bladder cancer [45]. In the same sense, Ishak et al.<br>388 demonstrated an EZH2-dependent silencing of genomic repeat sequences. 388 demonstrated an EZH2-dependent silencing of genomic repeat sequences,<br>389 including L1 elements [46]. Therefore additional analyses would be required to 389 including L1 elements [46]. Therefore, additional analyses would be required to<br>390 further address if this epigenetic network plays a role in cancer genome 390 further address if this epigenetic network plays a role in cancer genome<br>391 reorganization.  $\frac{1}{2}$  further address if the conduction.<br>  $\frac{1}{2}$   $\frac{1$ 

392 Then, to evalue 392 Then, to evaluate possible HNSCC early diagnosis potential biomarkers is<br>393 fundamental.to.get.insights.into.the.transition.from.pre-tumoral.to.cancer.disease.<br>394 Thus. we evaluated the presence of field cancerizatio 394 – Thus, we evaluated the presence of field cancerization and identified genetic<br>395 – features that can eventually lead to cancer development [47], finding exclusive 395 features that can eventually lead to cancer development [47], finding exclusive<br>396 somatic mutations in the NAT and a small proportion shared with the tumor. 396 – somatic mutations in the NAT and a small proportion shared with the tumor.<br>397 – Several studies have recently described patchworks of different clones in normal 397 Several studies have recently described patchworks of different clones in normal<br>398 tissues, some of them even bearing driver mutations, increasing with age or 398 tissues, some of them even bearing driver mutations, increasing with age or<br>399 smoking habits [48–50]. We found *NOTCH1* and *FAT1* as the most mutated genes. 399 smoking habits [48–50]. We found *NOTCH1* and *FAT1* as the most mutated genes,<br>400 as Martincorena's results in normal skin and esophagus [48,51]. These genes 399 400 as Martincorena´s results in normal skin and esophagus [48,51]. These genes<br>401 showed also high mutation rates in the tumor, indicating the presence of a 401 showed also high mutation rates in the tumor, indicating the presence of a<br>402 precancerous or cancer invasion field.  $\frac{3}{402}$  precancerous or cancer invasion field.<br> $\frac{402}{402}$  Finally, when are exploited 1.1 activity account makiliarians were exploringly

403 Finally, when we evaluated L1 activ<br>404 - Cancel MAT in Julius of the state 403 Finally, when we evaluated L1 activity, several mobilizations were exclusively<br>404 found in NAT, and only one appeared shared with the tumor, again supporting a<br>405 cancerization field. Somatic L1 retrotransposition ev 405 cancerization field. Somatic L1 retrotransposition events have been recently<br>406 described in normal urothelium and colorectal epithelium, although with much 406 described in normal urothelium and colorectal epithelium, although with much<br>407 lower rates than in bladder and colorectal cancer [52,53]. L1 activity has been also 407 lower rates than in bladder and colorectal cancer [52,53]. L1 activity has been also<br>408 described in a few pre-tumor samples including Barrett's esophagus and colorectal 408 described in a few pre-tumor samples including Barrett's esophagus and colorectal<br>409 adenomas [8,28,54]. Therefore, L1 activation arises as a reinforced early event, adenomas  $[8,28,54]$ . Therefore, L1 activation arises as a reinforced early event,  $\frac{1}{2}$ 

410 even in pre-tumor stages, in the natural history of HNSCC, with the associated<br>411 potential of L1 as a field cancerization biomarker.<br>412

# 412 potential of Linux and Linux 413<br>414

We present the development and benchmarking of RetroTest, which allows an<br>415 easy measurement of real L1 activation from small tumor biopsies with high<br>416 efficacy, favoring its implementation in real clinical settings. 416 efficacy, favoring its implementation in real clinical settings. RetroTest revealed<br>417 that most of the HNSCC patients present L1 activation, associated with smoking 417 that most of the HNSCC patients present L1 activation, associated with smoking<br>418 habits and already active in early stages of the disease and NAT. supporting a field 418 habits and already active in early stages of the disease and NAT, supporting a field<br>419 cancerization process and its potential as early diagnostic biomarker. 419 habita cancerization process and its potential as early diagnostic biomarker.<br>420 420<br>420<br>431 calmerides meets

### 421<br>422

414 We present t<br>415 easy measure<br>416 efficacy, favo<br>417 that most of<br>418 habits and alı<br>420 cancerization<br>420 Acknowledge<br>422 Authors than<br>423 was made pc<br>424 Center (CES<br>424 Center (CES<br>425 FinisTerrae I<br>426 Spanish Mini 422 Authors thank all the enrolled patients and their families. This research project<br>423 was made possible through the access granted by the Galician Supercomputing<br>424 Center (CESGA) to its supercomputing infrastructure. 424 Center (CESGA) to its supercomputing infrastructure. The supercomputer<br>425 FinisTerrae III and its permanent data storage system have been funded by the 425 FinisTerrae III and its permanent data storage system have been funded by the<br>426 Spanish Ministry of Science and Innovation, the Galician Government and the 426 Spanish Ministry of Science and Innovation, the Galician Government and the<br>427 European Regional Development Fund (ERDF). 427 European Regional Development Fund (ERDF).<br>428 This work was supported by the Instituto de

422 Authors thank all the<br>423 was made possible ti<br>424 Center (CESGA) to<br>425 FinisTerrae III and it<br>426 Spanish Ministry of<br>427 European Regional De<br>428 This work was supp<br>429 European Social Fun<br>430 by P121/00208, co-f<br>43 428 This work was supported by the Instituto de Salud Carlos III (ISCIII) and the<br>429 European Social Fund ("Investing in your future") (PI19/01113, and partially 429 European Social Fund ("Investing in your future") (PI19/01113, and partially<br>430 by P121/00208, co-funded by FEDER and the European Union), and the Spanish 430 by P121/00208, co-funded by FEDER and the European Union), and the Spanish<br>431 Association Against Cancer Scientific Foundation (IDEAS19122MART). A.O. was 431 Association Against Cancer Scientific Foundation (IDEAS19122MART). A.O. was<br>432 supported by a predoctoral fellowship from the Galician Innovation Agency, Xunta 432 supported by a predoctoral fellowship from the Galician Innovation Agency, Xunta<br>433 de Galicia (ED481A-2020/214). M.M.-F. and J.B. were previously supported by the 433 de Galicia (ED481A-2020/214). M.M.-F. and J.B. were previously supported by the<br>434 Spanish Association Against Cancer Scientific Foundation (INVES207MART and Spanish Association Against Cancer Scientific Foundation (INVES207MART and  $\frac{1}{4}$  Spanish Association Against Cancer Scientific Foundation  $\frac{1}{15}$ 



## 441<br>442

- 
- 443 for this work (CEIC 2018/567).
- 

# 444 for the work (CEIC 2018). 444<br>445<br>446

- 
- 

# 447  $\frac{1}{6}$ 447<br>448<br>449

- 
- 

# 450  $\frac{454}{\pi}$  Pote cycle bility statement. 450<br>451<br>452

- 
- Whole Genome Sequencing data from the HNSCC cohort is deposited into the<br>453 Sequence Read Archive (SRA) repository under the following BioProject ID:<br>454 PRJNA1053897. RetroTest pipeline is publicly available at
- 454 PRJNA1053897. RetroTest pipeline is publicly available at<br>454 PRJNA1053897. RetroTest pipeline is publicly available at
- 455 <u>https://gitlab.com/mobilegenomesgroup/RETROTEST</u><br>456
- 

# $\frac{1}{456}$ <br>456 https://gitlab.com/mobilegenomes/spromessary/RETROTEST.com/mobilegenomes/spromessary/RETROTEST.com/mobilegenomes/spromessary/RETROTEST.com/mobilegenomes/spromessary/RETROTEST.com/mobilegenomes/spromessary/ 457<br>458

The Ethical Commistant<br>442 The Ethical Commistant<br>443 for this work (CEIC<br>444 **Competing intere**<br>446 The authors declar<br>447 **Consent for publi**<br>449 All authors give co<br>450 All authors give co<br>450 Data availability :<br>452 Wh The authors declare no<br>
446 The authors declare no<br>
447 **Consent for publicati**<br>
449 All authors give conser<br>
450 **Data availability stat**<br>
452 Whole Genome Seque<br>
453 Sequence Read Archi<br>
454 PRJNA1053897. R<br>
455 <u>https:/</u> 2012 2012 2012 2012<br>
449 All authors give consent for<br>
450<br>
451 Data availability statement<br>
452 Whole Genome Sequenci<br>
453 Sequence Read Archive<br>
454 PRJNA1053897. Retro<br>
454 <u>PRJNA1053897.</u> Retro<br>
455 <u>https://gitlab.com</u> 452 Whole Genome Sequencing<br>453 Sequence Read Archive (SR<br>454 PRJNA1053897. RetroTes<br>455 <u>https://gitlab.com/mobileger</u><br>456 CRediT authorship contribu<br>458 Jenifer Brea-Iglesias and<br>459 Software, Data curation, Inve 458 **Jenifer Brea-Iglesias and Ana Oitabén**:<br>459 Software, Data curation, Investigation, Valida<sup>.</sup><br>159 Software, Data curation, Investigation, Valida. 1459 Software, Data curation, Investigation, Validation, Visualization, Writing – review<br>16  $\frac{3}{5}$ 9 Software, Data curation, Validation, Visualization, Writing  $\frac{3}{5}$ 

460 Software, Validation, Writing – review and editing. Bernardo Rodríguez-Martin:<br>
462 Conceptualization, Methodology, Software. María Gallardo-Gómez:<br>
463 Conceptualization, Visualization, Writing – review and editing Ma 462 Conceptualization, Methodology, Software. Muria Gallardo-Gómez:<br>
463 Conceptualization, Visualization, Writing – review and editing Martin<br>
464 Santamarrina: Methodology, Validation. Ana Pequeño-Valtierra:<br>
465 Concept 463 Conceptualization, Visualization, Writing – review and editing Martin<br>1464 Santamarina: Methodology, Validation. Ana Pequeño-Valtierra:<br>1465 Conceptualization, Investigation. Laura Juaneda-Magdalena: Methodology,<br>1466 464 **Santamarina:** Methodology, Validation. Ana Pequeño-Valtierra:<br>
465 Conceptualization, Investigation. Laura Juaneda-Magdalena: Methodology,<br>
466 Conceptualization, Writing - review and editing. Ramón García-Escudero:<br> 965 Conceptualization, Investigation. Laura Juaneda-Magdalena: Methodology, Conceptualization, Writing - review and editing Ramón García-Escudero:<br>
467 Methodology, Writing - review and editing Jose Luis López-Cedrún:<br>
468 466 Conceptualization, Writing - review and editing Ramón García-Escudero:<br>
467 Methodology, Writing - review and editing Jose Luis López-Cedrún:<br>
468 Methodology, Máximo Fraga: Funding acquisition. José MC Tublo:<br>
469 Con Methodology. Writing - review and editing Jose Luis López-Cedrún:<br>
Methodology. Máximo Fraga: Funding acquisition. José MC Tubio:<br>
Conceptualization, Funding sequisition. Mónica Martínez-Fernández: Writing<br>
- review & edit Methodology, Maximo Fraga: Funding acquisition. José MC Tubio:<br>
469 Methodology, Maximo Fraga: Funding acquisition. Monica Martinez-Fernández: Writing - review & editing. Writing - original draft, Supervision, Resources, I 469 Conceptualization, Funding acquisition. **Mónica Martínez-Fernández:** Writing<br>
470 review & editing, Writing – original draft, Supervision, Resources, Investigation,<br>
471 Project administration, Funding acquisition, Co eview & editing, Writing – original draft, Supervision, Resources, Investigation,<br>
Project administration, Funding acquisition. Conceptualization. All authors<br>
approved the final version.<br>
473<br>
References<br>
1473<br>
References 170 review & editing, Writing – original draft, Supervision, Resources, Investigation,<br>171 Project administration, Funding acquisition, Conceptualization. All authors<br>172 approved the final version. 472 approved the final version,  $\frac{c}{c}$  and  $\frac{c}{c}$  and  $\frac{c}{c}$  authors are proved the final version. 473<br>473<br>474 approved the final version.

# 473<br>474<br>475

- 475 [1] H.H. K<br>476 genom<br>477 [2] E.S. La<br>478 Devon<br>479 Heafon<br>480 McKer<br>481 Raymo<br>482 N. Stoj<br>483 S. Becl<br>484 Deloul 475 [1] H.H. Kazazian, J. V. Moran, The impact of L1 retrotransposons on the human
- 477 [2] E.S. Lander, L.M. Linton, B. Birren, C. Nusbaum, M.C. Zody, J. Baldwin, K.<br>478 Devon, K. Dewar, M. Doyle, W. Fitzhugh, R. Funke, D. Gage, K. Harris, A.

477 [2] E.S. Lander, L.M. Linton, B. Birren, C. Nusbaum, M.C. Zody, J. Baldwin, K.

- 478 Devon, K. Dewar, M. Doyle, W. Fitzhugh, R. Funke, D. Gage, K. Harris, A.
- 480 McKernan, J. Meldrim, J.P. Mesirov, C. Miranda, W. Morris, J. Naylor, C.<br>481 Raymond, M. Rosetti, R. Santos, A. Sheridan, C. Sougnez, N. Stange-Tho
- 480 McKernan, J. Meldrim, J.P. Mesirov, C. Miranda, W. Morris, J. Naylor, C.
- 481 Raymond, M. Rosetti, R. Santos, A. Sheridan, C. Sougnez, N. Stange-Thomann,
- 483 S. Beck, D. Bentley, J. Burton, C. Clee, N. Carter, A. Coulson, R. Deadman, P.<br>484 Deloukas, A. Dunham, I. Dunham, R. Durbin, L. French, D. Grafham, S.
- Deloukas, A. Dunham, I. Dunham, R. Durbin, L. French, D. Grafham, S. 484 Deloukas, A. Dunham, I. Dunham, R. Durbin, L. French, D. Grafham, S.





- 511 Schuler, J. Schultz, G. Slater, A.F.A. Smit, E. Stupka, J. Szustakowki, D. Thierry-<br>512 Mieg, J. Thierry-Mieg, L. Wagner, J. Wallis, R. Wheeler, A. Williams, Y.I. Wolf,
- 
- 511 Schuler, J. Schultz, G. Slater, A.F.A. Smit, E. Stupka, J. Szustakowki, D. Thierry-513 K.H. Wolfe, S.P. Yang, R.F. Yeh, F. Collins, M.S. Guyer, J. Peterson, A.<br>514 S.J. Wheeler, A. Williams, A. R. W. M. Wolf, A. Williams, Y.C. N. W. R. W. R. L. 513 K.H. Wolfe, S.P. Yang, R.F. Yeh, F. Collins, M.S. Guyer, J. Peterson, A.<br>514 Felsenfeld, K.A. Wetterstrand, R.M. Myers, J. Schmutz, M. Dickson, J.<br>515 Grimwood, D.R. Cox. M. V. Olson. R. Kaul. C. Ravmond. N. Shimizu. K
- 
- 514 Felsenfeld, K.A. Wetterstrand, R.M. Myers, J. Schmutz, M. Dickson, J.
- 515 Grimwood, D.R. Cox, M. V. Olson, R. Kaul, C. Raymond, N. Shimizu, K.
- 517 M.J. Morgan, Initial sequencing and analysis of the human genome, Nature<br>518 409 (2001) 860–921. https://doi.org/10.1038/35057062.
- 518 M.J. Morgan, 109 (2001) 860–921. https://doi.org/10.1038/35057062.<br>19 J. G.R. Beck, P. Collier, C. Macfarlane, M. Malig, J.M. Kidd, E.E. E.
- 519 [3] C.R. Beck, P. Collier, C. Macfarlane, M. Malig, J.M. Kidd, E.E. Eichler, R.M.<br>520 Badge. I. V. Moran. LINE-1 retrotransposition activity in human genome
- 519 [3] C.R. Beck, P. Collier, C. Macfarlane, M. Malig, J.M. Kidd, E.E. Eichler, R.M.
- $521$  Gell 141 (2010) 1159–1170.<br> $522$  Gell 141 (2010) 1159–1170.
- 522 [4] B. Brouha, J. Schustak, R.M. Badge, S. Lutz-Prigge, A.H. Farley, J. V. Morant,<br>523 H.H. Kazazian. Hot L1s account for the bulk of retrotransposition in the
- 523 H.H. Kazazian, Hot L1s account for the bulk of retrotransposition in the<br>524 human population, Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 5280–5285.
- 524 human population, Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 5280–5285.<br>525 [5] S.J. Hoyt, J.M. Storer, G.A. Hartley, P.G.S. Grady, A. Gershman, L.G. de Lima
- 525 [5] S.J. Hoyt, J.M. Storer, G.A. Hartley, P.G.S. Grady, A. Gershman, L.G. de Lima, C.<br>526 Limouse. R. Halabian. L. Woienski. M. Rodriguez. N. Altemose. A. Rhie. L.I.
- 525 [5] S.J. Hoyt, J.M. Storer, G.A. Hartley, P.G.S. Grady, A. Gershman, L.G. de Lima, C.
- 527 Core, J.L. Gerton, W. Makalowski, D. Olson, J. Rosen, A.F.A. Smit, A.F. Straight,<br>528 M.R. Vollger. T.I. Wheeler. M.C. Schatz. E.E. Eichler. A.M. Phillippy. W. Timp.
- 528 M.R. Vollger, T.J. Wheeler, M.C. Schatz, E.E. Eichler, A.M. Phillippy, W. Timp,<br>529 K.H. Miga. R.I. O'Neill. From telomere to telomere: The transcriptional and
- 528 M.R. Vollger, T.J. Wheeler, M.C. Schatz, E.E. Eichler, A.M. Phillippy, W. Timp,
- 530 epigenetic state of human repeat elements, Science. 376 (2022).<br>531 https://doi.org/10.1126/science.abk3112.
- 531 https://doi.org/10.1126/science.abk3112.<br>532 [6] D.M. Sassaman, B.A. Dombroski, J. V. Moran,
- 532 [6] D.M. Sassaman, B.A. Dombroski, J. V. Moran, M.L. Kimberland, T.P. Naas, R.J.<br>533 DeBerardinis, A. Gabriel, G.D. Swergold, H.H. Kazazian, Many human L1
- 532 [6] D.M. Sassaman, B.A. Dombroski, J. V. Moran, M.L. Kimberland, T.P. Naas, R.J.
- elements are capable of retrotransposition, Nat. Genet. 16 (1997) 37-43. 534 elements are capable of retrotransposition, Nat. Genet. 16 (1997) 37–43.

- 535 [7] J.M.C. e. al Tubio, Extensive transduction of nonrepetitive DNA mediated by<br>536 L1 retrotransposition in cancer genomes, Science. 345 (2014) 1251343.<br>537 https://doi.org/10.1126/science.1251343.Extensive.
- 
- 537 https://doi.org/10.1126/science.1251343.Extensive.<br>538 [8] A.D. Ewing, A. Gacita, L.D. Wood, F. Ma, D. Xing, M.S. Ki
- 538 [8] A.D. Ewing, A. Gacita, L.D. Wood, F. Ma, D. Xing, M.S. Kim, S.S. Manda, G. Abril,<br>539 G. Pereira. A. Makohon-Moore. L.H.I. Looiienga. A.I.M. Gillis. R.H. Hruban. R.A.
- 538 [8] A.D. Ewing, A. Gacita, L.D. Wood, F. Ma, D. Xing, M.S. Kim, S.S. Manda, G. Abril,
- 539 G. Pereira, A. Makohon-Moore, L.H.J. Looijenga, A.J.M. Gillis, R.H. Hruban, R.A.
- 540 Anders, K.E. Romans, A. Pandey, C.A. Iacobuzio-Donahue, B. Vogelstein, K.W.
- 542 occurs early during gastrointestinal cancer evolution, Genome Res. 25<br>543 (2015) 1536–1545. https://doi.org/10.1101/gr.196238.115.

542 occurs early during gastrointestinal cancer evolution, Genome Res. 25

544 [9] B. Rodriguez-Martin, E.G. Alvarez, A. Baez-Ortega, J. Zamora, F. Supek, J.<br>545 Demeulemeester. M. Santamarina. Y.S. Iu. I. Temes. D. Garcia-Souto. H.

544 [9] B. Rodriguez-Martin, E.G. Alvarez, A. Baez-Ortega, J. Zamora, F. Supek, J.

- 546 Detering, Y. Li, J. Rodriguez-Castro, A. Dueso-Barroso, A.L. Bruzos, S.C.<br>547 Dentro, M.G. Blanco, G. Contino, D. Ardeljan, M. Tojo, N.D. Roberts, S.
- 547 Dentro, M.G. Blanco, G. Contino, D. Ardeljan, M. Tojo, N.D. Roberts, S.<br>548 Zumalave, P.A.W. Edwards, J. Weischenfeldt, M. Puiggròs, Z. Chong, K
- 547 Dentro, M.G. Blanco, G. Contino, D. Ardeljan, M. Tojo, N.D. Roberts, S.
- 548 Zumalave, P.A.W. Edwards, J. Weischenfeldt, M. Puiggròs, Z. Chong, K. Chen,
- 549 E.A. Lee, J.A. Wala, K. Raine, A. Butler, S.M. Waszak, F.C.P. Navarro, S.E.
- 551 D.C. Wedge, R. Beroukhim, D. Torrents, J.O. Korbel, I.I. Martincorena, R.C.<br>552 Fitzgerald, P. Van Loo, H.H. Kazazian, K.H. Burns, K.C. Akdemir, E.G. Alvar
- 552 Fitzgerald, P. Van Loo, H.H. Kazazian, K.H. Burns, K.C. Akdemir, E.G. Alvarez,<br>553 A. Baez-Ortega, R. Beroukhim, P.C. Boutros, D.D.L. Bowtell, B. Brors, K.H.
- 553 A. Baez-Ortega, R. Beroukhim, P.C. Boutros, D.D.L. Bowtell, B. Brors, K.H.<br>554 Burns, P.J. Campbell, K. Chan, I. Cortés-Ciriano, A. Dueso-Barroso, A.J.
- 554 Burns, P.J. Campbell, K. Chan, I. Cortés-Ciriano, A. Dueso-Barroso, A.J.<br>555 Dunford. P.A.W. Edwards. X. Estivill. D. Etemadmoghadam. L. Feuerba
- 554 Burns, P.J. Campbell, K. Chan, I. Cortés-Ciriano, A. Dueso-Barroso, A.J.
- 555 Dunford, P.A.W. Edwards, X. Estivill, D. Etemadmoghadam, L. Feuerbach, J.L.
- 557 Finan, J.E. Haber, J.M. Hess, B. Hutter, M. Imielinski, D.T.W. Jones, M.D.<br>558 Fink, L.J. Klimczak, Y. Koh, J.O. Korbel, K. Kumar, E.A. Lee, J.J.K. Lee
- 558 Kazanov, L.J. Klimczak, Y. Koh, J.O. Korbel, K. Kumar, E.A. Lee, J.J.K. Lee, Y. Li,<br>559 A.G. Lynch, G. Macintyre, F. Markowetz, A. Martinez-Fundichely, M.
- A.G. Lynch, G. Macintyre, F. Markowetz, A. Martinez-Fundichely, M. 559 A.G. Lynch, G. Macintyre, F. Markowetz, A. Martinez-Fundichely, M.



584 head and neck cancer, Nat. Rev. Cancer 11 (2011) 9–22.

- 585 https://doi.org/10.1038/nrc2982.<br>586 [13] H. Li, Aligning sequence reads, clone sequences and assembly contigs with<br>587 BWA-MEM, ArXiv: Genomics (2013).
- $587$  BWA-MEM, ArXiv: Genomics (2013).
- 588 https://doi.org/10.6084/M9.FIGSHARE.963153.V1.<br>589 [14] P. Danecek, I.K. Bonfield, I. Liddle, I. Marshall, V. Ohar
- 589 [14] P. Danecek, J.K. Bonfield, J. Liddle, J. Marshall, V. Ohan, M.O. Pollard, A.<br>590 Whitwham. T. Keane. S.A. McCarthy. R.M. Davies. Twelve vears of SAM
- 589 [14] P. Danecek, J.K. Bonfield, J. Liddle, J. Marshall, V. Ohan, M.O. Pollard, A.
- 591 and BCFtools, Gigascience 10 (2021) 1–4.<br>592 https://doi.org/10.1093/GIGASCIENCE/C
- 592 https://doi.org/10.1093/GIGASCIENCE/GIAB008.<br>593 [15] Broad Institute. Picard Tools. Http://Broadinstitute
- 593 [15] Broad Institute, Picard Tools, Http://Broadinstitute.Github.Io/Picard/ (n.d.).<br>594 [16] W. Huang. L. Li. J.R. Myers. G.T. Marth. ART: a next-generation sequencing
- 593 [15] Broad Institute, Picard Tools, Http://Broadinstitute.Github.Io/Picard/ (n.d.).
- 594 [16] W. Huang, L. Li, J.R. Myers, G.T. Marth, ART: a next-generation sequencing
- 596 https://doi.org/10.1093/BIOINFORMATICS/BTR708.<br>597 [17] A.R. Quinlan, I.M. Hall, BEDTools: a flexible suite of util
- 596 https://doi.org/10.1093/BIOINFORMATICS/BTR708.
- 598 genomic features, Bioinformatics 26 (2010) 841–842.<br>599 https://doi.org/10.1093/BIOINFORMATICS/BTO033.
- 599 https://doi.org/10.1093/BIOINFORMATICS/BTQ033.<br>600 [18] M. V. Kuleshov, M.R. Jones, A.D. Rouillard, N.F. Fernand
- 600 [18] M. V. Kuleshov, M.R. Jones, A.D. Rouillard, N.F. Fernandez, Q. Duan, Z. Wang,<br>601 S. Koplev. S.L. Jenkins. K.M. Jagodnik. A. Lachmann. M.G. McDermott. C.D.
- 600 [18] M. V. Kuleshov, M.R. Jones, A.D. Rouillard, N.F. Fernandez, Q. Duan, Z. Wang,
- 601 S. Koplev, S.L. Jenkins, K.M. Jagodnik, A. Lachmann, M.G. McDermott, C.D.
- 602 Monteiro, G.W. Gundersen, A. Maayan, Enrichr: a comprehensive gene set
- 604 w90-W97. https://doi.org/10.1093/NAR/GKW377.<br>605 [19] D. Ardeljan, M.S. Taylor, D.T. Ting, K.H. Burns, The Hu
- 605 [19] D. Ardeljan, M.S. Taylor, D.T. Ting, K.H. Burns, The Human Long Interspersed<br>606 Element-1 Retrotransposon: An Emerging Biomarker of Neoplasia. Clin.
- 605 [19] D. Ardeljan, M.S. Taylor, D.T. Ting, K.H. Burns, The Human Long Interspersed
- $607$  Chem. 63 (2017) 816-822.
- 608 https://doi.org/10.1373/CLINCHEM.2016.257444.<br>609 [20] M.L. Filipenko, U.A. Boyarskikh, L.S. Leskov, K. V. Sul
- [20] M.L. Filipenko, U.A. Boyarskikh, L.S. Leskov, K. V. Subbotina, E.A. Khrapov, A. 609 [20] M.L. Filipenko, U.A. Boyarskikh, L.S. Leskov, K. V. Subbotina, E.A. Khrapov, A.



- 610 V. Sokolov, I.S. Stilidi, N.E. Kushlinskii, The Level of LINE-1 mRNA Is
- 611 Increased in Extracellular Circulating Plasma RNA in Patients with
- 613 https://doi.org/10.1007/S10517-022-05530-2/METRICS.<br>614 [21] S. Sato. M. Gillette. P.R. de Santiago. E. Kuhn. M. Burgess. K. ]
- 614 [21] S. Sato, M. Gillette, P.R. de Santiago, E. Kuhn, M. Burgess, K. Doucette, Y. Feng,<br>615 C. Mendez-Dorantes. P.I. Ippoliti. S. Hobdav. M.A. Mitchell. K. Doberstein. S.M.
- 614 [21] S. Sato, M. Gillette, P.R. de Santiago, E. Kuhn, M. Burgess, K. Doucette, Y. Feng,
- 616 Gysler, M.S. Hirsch, L. Schwartz, M.J. Birrer, S.J. Skates, K.H. Burns, S.A. Carr,<br>617 R. Drapkin, LINE-1 ORF1p as a candidate biomarker in high grade serous
- 616 Gysler, M.S. Hirsch, L. Schwartz, M.J. Birrer, S.J. Skates, K.H. Burns, S.A. Carr,
- 618 ovarian carcinoma, Sci. Rep. 13 (2023). https://doi.org/10.1038/s41598-<br>619 023-28840-5.
- 
- 619 ovariant care care the care is the computer of the care of th 620 [22] M.S. Taylor, C.
- 620 [22] M.S. Taylor, C. Wu, P.C. Fridy, S.J. Zhang, Y. Senussi, J.C. Wolters, T. Cajuso, W.-
- 621 C. Cheng, J.D. Heaps, B.D. Miller, K. Mori, L. Cohen, H. Jiang, K.R. Molloy, B.T.
- 622 Chait, M.G. Goggins, I. Bhan, J.W. Franses, X. Yang, M.-E. Taplin, X. Wang, D.C.
- 623 Christiani, B.E. Johnson, M. Meyerson, R. Uppaluri, A.M. Egloff, E.N. Denault,
- 624 L.M. Spring, T.-L. Wang, I.-M. Shih, J.E. Fairman, E. Jung, K.S. Arora, O.H.
- 625 Yilmaz, S. Cohen, T. Sharova, G. Chi, B.L. Norden, Y. Song, L.T. Nieman, L.
- 626 Pappas, A.R. Parikh, M.R. Strickland, R.B. Corcoran, T. Mustelin, G. Eng, O.H.
- 628 Deshpande, D.T. Ting, M.P. Rout, J. LaCava, D.R. Walt, K.H. Burns,<br>629 Ultrasensitive detection of circulating LINE-1 ORF1p as a specific
- 628 Deshpande, D.T. Ting, M.P. Rout, J. LaCava, D.R. Walt, K.H. Burns,
- 
- $624$  Ultrasensitive detection of contrastence of contrastence multi- $631$  https://doi.org/10.1158/2159-8290.CD-23-<br> $632$  0212/320025/AM/UUTDASENSULUE DETECTION OF G
- 631 https://doi.org/10.1158/2159-8290.CD-23-<br>632 0313/729035/AM/ULTRASENSITIVE-DETECTION-OF-CIRCULATING-LINE-<br>633 1.
- 
- $634$  031 UV D-illis MM/D<sub>repre</sub>sht VD Hoters DJ Cooks odk TA Diskus ord F.D. ---<br>634 [23] J.K 634 [23] J.K. Baillie, M.W. Barnett, K.R. Upton, D.J. Gerhardt, T.A. Richmond, F. De

- 
- 635 Sapio, P.M. Brennan, P. Rizzu, S. Smith, M. Fell, R.T. Talbot, S. Gustincich, T.C.<br>636 Freeman, J.S. Mattick, D.A. Hume, P. Heutink, P. Carninci, J.A. Jeddeloh, G.J.<br>637 Faulkner, Somatic retrotransposition alters the
- 637 Faulkner, Somatic retrotransposition alters the genetic landscape of the<br>638 human brain, Nature 479 (2011) 534–537
- 637 Faulkner, Somatic retrotransposition alters the genetic landscape of the
- 639 https://doi.org/10.1038/nature10531.<br>640 [24] C. Chu. R. Borges-Monrov. V. V. Viswana
- 639 https://doi.org/10.1038/nature10531.
- 640 [24] C. Chu, R. Borges-Monroy, V. V. Viswanadham, S. Lee, H. Li, E.A. Lee, P.J. Park,

642 multiple sequencing technologies, Nat. Commun. 12 (2021).<br>643 https://doi.org/10.1038/s41467-021-24041-8.

- 643 https://doi.org/10.1038/s41467-021-24041-8.<br>644 [25] E.J. Gardner, V.K. Lam, D.N. Harris, N.T. Chuang, I
- 643 https://doi.org/10.1038/s41467-021-24041-8.
- 644 [25] E.J. Gardner, V.K. Lam, D.N. Harris, N.T. Chuang, E.C. Scott, W. Stephen
- 646 Population-scale mobile element discovery and biology, Genome Res. 27<br>647 (2017) 1916–1929. https://doi.org/10.1101/GR.218032.116/-/DC1.
- 646 Population-scale mobile element discovery and biology, Genome Res. 27
- 647 (2017) 1916–1929. https://doi.org/10.1101/GR.218032.116/-/DC1.
- 648 [26] D.T. jwa. Thung, J. de Ligt, L.E.M. Vissers, M. Steehouwer, M. Kroon, P. de
- 649 Vries, E.P. Slagboom, K. Ye, J.A. Veltman, J.Y. Hehir-Kwa, Mobster: accurate
- 651 Genome Biol. 15 (2014) 488. https://doi.org/10.1186/S13059-014-0488-<br>652 X/FIGURES/3.

- 651 Genome Biol. 15 (2014) 488. https://doi.org/10.1186/S13059-014-0488- 653 [27] W. Zhou, S.B. E.
- 653 [27] W. Zhou, S.B. Emery, D.A. Flasch, Y. Wang, K.Y. Kwan, J.M. Kidd, J. V. Moran,<br>654 R.E. Mills, Identification and characterization of occult human-specific LINE-<br>655 1 insertions using long-read sequencing technolo
- 
- $656$   $(2020)$   $1146$   $1462$  L<sub>H</sub>  $(11)$   $(1000)$  (NAD  $(61771172)$  $\frac{6}{5}$  656 (2020) 1146-1163. https://doi.org/10.1093/NAR/GKZ1173.
- 656 (2020) 1146–1163. https://doi.org/10.1093/NAR/GKZ1173.<br>657 [28] A.C. Katz-Summercorn, S. Jammula, A. Frangou, I. Peneva, M. O'Donovan, M.<br>658 Tripathi, S. Malhotra,
- 657 [28] A.C. Katz-Summercorn, S. Jammula, A. Frangou, I. Peneva, M. O'Donovan, M.
- Blasko, K. Nowicki-Osuch, S. MacRae, A. Northrop, A.M. Redmond, D.C. 659 Blasko, K. Nowicki-Osuch, S. MacRae, A. Northrop, A.M. Redmond, D.C.

- 660 Wedge, R.C. Fitzgerald, Multi-omic cross-sectional cohort study of pre-
- 
- $662$  wetwo realization of provided, Mat. Commun. 12 (2022) malignant Barrett's esophagus reveals early structural variation and<br>662 metrotransposon activity, Nat. Commun. 13 (2022).<br>662 metrotransposon activity, Nat. Commun. 13 (2022). 662 retrotransposon activity, Nat. Commun. 13 (202<br>663 https://doi.org/10.1038/s41467-022-28237-4.<br>664 [29] A.W. Caliri. A. Caceres. S. Tommasi. A. Besaratini
- 
- 663 https://doi.org/10.1038/s41467-022-28237-4.
- 
- $666$  a.w. California, A.W. California, A.W. Caceres, S. Tommas in T. Tommas in Line-15 (2002) 046-020.  $666$  smokers, Epigenetics 15 (2020) 816–829.<br> $667$  https://dai.org/10.1090/15503394.3939.1734491.
- 667 https://doi.org/10.1080/15592294.2020.1724401.<br>668 [30] H. Shigaki, Y. Baba, M. Watanabe, S. Iwagami, K. Miya
- 668 [30] H. Shigaki, Y. Baba, M. Watanabe, S. Iwagami, K. Miyake, T. Ishimoto, M.<br>669 Iwatsuki. H. Baba. LINE-1 hypomethylation in noncancerous esophagea
- 668 [30] H. Shigaki, Y. Baba, M. Watanabe, S. Iwagami, K. Miyake, T. Ishimoto, M.
- 670 mucosae is associated with smoking history, Ann. Surg. Oncol. 19 (2012)<br>671 4238–4243. https://doi.org/10.1245/s10434-012-2488-y.

671 4238–4243. https://doi.org/10.1245/s10434-012-2488-y<br>672 [31] P. Vineis, M. Alavanja, P. Buffler, E. Fontham, S. Franceschi, Y

672 [31] P. Vineis, M. Alavanja, P. Buffler, E. Fontham, S. Franceschi, Y.T. Gao, P.C.<br>673 Gupta, A. Hackshaw, E. Matos, J. Samet, F. Sitas, J. Smith, L. Stayner, K. Str

672 [31] P. Vineis, M. Alavanja, P. Buffler, E. Fontham, S. Franceschi, Y.T. Gao, P.C.

- 673 Gupta, A. Hackshaw, E. Matos, J. Samet, F. Sitas, J. Smith, L. Stayner, K. Straif,
- 674 M.J. Thun, H.E. Wichmann, A.H. Wu, D. Zaridze, R. Peto, R. Doll, Tobacco and
- 676 cancer: 106. https://doi.org/10.1093/JNCI/DJH014.<br>677 [32] K. Hur, P. Cejas, J. Feliu, J. Moreno-Rubio, E. B
- 677 [32] K. Hur, P. Cejas, J. Feliu, J. Moreno-Rubio, E. Burgos, C.R. Boland, A. Goel,<br>678 Hvnomethvlation of long interspersed nuclear element-1 (LINE-1) leads

677 [32] K. Hur, P. Cejas, J. Feliu, J. Moreno-Rubio, E. Burgos, C.R. Boland, A. Goel,

679 hypoto-oncogenes in human colorectal cancer metastasis, Gut 63<br>680 (2014) 635–646. https://doi.org/10.1136/GUTINL-2012-304219.

679 activation of proto-oncogenes in human colorectal cancer metastasis, Gut 63

- 680 (2014) 635–646. https://doi.org/10.1136/GUTJNL-2012-304219.
- 681 [33] M. Casarotto, V. Lupato, G. Giurato, R. Guerrieri, S. Sulfaro, A. Salvati, E.
- 682 D'Angelo, C. Furlan, A. Menegaldo, L. Baboci, B. Montico, I. Turturici, R.
- Giacomarra, G. Franchin, A. Steffan, L. Sigalotti, E. Vaccher, P. Boscolo-Rizzo, 684 Giacomarra, G. Franchin, A. Steffan, L. Sigalotti, E. Vaccher, P. Boscolo-Rizzo,





- hallmark of many human cancers, Am. J. Pathol. 184 (2014) 1280–1286.<br>736 https://doi.org/10.1016/j.ajpath.2014.01.007.<br>737 [44] D. Mangoni, A. Simi, P. Lau, A. Armaos, F. Ansaloni, A. Codino, D. Damiani,
- 
- 737 [44] D. Mangoni, A. Simi, P. Lau, A. Armaos, F. Ansaloni, A. Codino, D. Damiani, L.<br>738 Floreani, V. Di Carlo, D. Vozzi, F. Persichetti, C. Santoro, L. Pandolfini, G.G.
- 738 Floreani, V. Di Carlo, D. Vozzi, F. Persichetti, C. Santoro, L. Pandolfini, G.G.<br>739 Tartaglia. R. Sanges. S. Gustincich. LINE-1 regulates cortical development
- 738 Floreani, V. Di Carlo, D. Vozzi, F. Persichetti, C. Santoro, L. Pandolfini, G.G.
- 739 Tartaglia, R. Sanges, S. Gustincich, LINE-1 regulates cortical development by
- 741 https://doi.org/10.1038/s41467-023-40743-7.<br>742 [45] M. Martínez-Fernández, A. Feber, M. Dueñas, C. S
- 742 [45] M. Martínez-Fernández, A. Feber, M. Dueñas, C. Segovia, C. Rubio, M.<br>743 Fernandez. F. Villacampa. I. Duarte. F.F. López-Calderón. M.I. Gómez-
- 743 Fernandez, F. Villacampa, J. Duarte, F.F. López-Calderón, M.J. Gómez-<br>744 Rodriguez, D. Castellano, J.L. Rodriguez-Peralto, F. De La Rosa, S. Beck, J.M.
- 
- $745$  Fernandez,  $\frac{1}{245}$  Fernandez, F. Villacampa, F. Villacampa, M.J. Gómez-Calderón, M.J. 245 Paramio, Analysis of the polycomb-related lncRNAs HOTAIR and ANRIL in<br>246 bladder server Clin Reisensties 7.0045) https://dei.org/10.1196/s1214
- 746 bladder cancer, Clin. Epigenetics 7 (2015). https://doi.org/10.1186/s13148-<br>747 015-0141-x.  $747$  015-0141-x.<br>746 E461 CANLINAE MULLEER, CRIMINAE MUCLISC
- 
- 748 [46] C.A. Ishak, A.E. Marshall, D.T. Passos, C.R. White, J. Seung, M.J. Cecchini, S.<br>749 Ferwati. W.A. Macdonald. I. Christopher. I.D. Welch. S.M. Rubin. M.R.W.
- 748 [46] C.A. Ishak, A.E. Marshall, D.T. Passos, C.R. White, J. Seung, M.J. Cecchini, S.
- 750 Mann, F.A. Dick, An RB-EZH2 Complex Mediates Silencing of Repetitive DNA<br>751 Sequences, 64 (2017) 1074–1087.
- $751$  Sequences, 64 (2017) 1074-1087.<br> $752$  by the subdivers (10.1016 (in plate 12016 10.021 April 12016)
- 752 https://doi.org/10.1016/j.molcel.2016.10.021.An.<br>753 [47] P. V. Angadi, J.K. Savitha, S.S. Rao, R.Y. Sivaranjini, 0
- 752 https://doi.org/10.1016/j.molcel.2016.10.021.An.
- 753 [47] P. V. Angadi, J.K. Savitha, S.S. Rao, R.Y. Sivaranjini, Oral field cancerization:
- 754 Current evidence and future perspectives, Oral Maxillofac. Surg. 16 (2012)
- 756 [48] I. Martincorena, A. Roshan, M. Gerstung, P. Ellis, P. Van Loo, S. McLaren, D.C.<br>757 Wedge, A. Fullam, L.B. Alexandrov, J.M. Tubio, L. Stebbings, A. Menzies, S.
- 756 [48] I. Martincorena, A. Roshan, M. Gerstung, P. Ellis, P. Van Loo, S. McLaren, D.C.
- 757 Wedge, A. Fullam, L.B. Alexandrov, J.M. Tubio, L. Stebbings, A. Menzies, S.
- positive selection of somatic mutations in normal human skin, Science. 348  $\frac{1}{2}$

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.07.24.24310921;](https://doi.org/10.1101/2024.07.24.24310921) this version posted July 29, 2024. The copyright holder for this preprint



- 761 https://doi.org/10.1126/SCIENCE.AAA6806/SUPPL\_FILE/AAA6806-<br>762 MARTINCORENA-SM.PDF.
- 1962 https://doi.org/10.1126/Supplement.com/2011<br>762 MARTINCORENA-SM.PDF.<br>762 MARTINCORENA-SM.PDF.
- 763 [49] K. Yoshida, K.H.C. Gowers, H. Lee-Six, D.P. Chandrasekharan, T. Coorens, E.F.<br>764 Maughan. K. Beal. A. Menzies. F.R. Millar. E. Anderson. S.E. Clarke. A.
- 763 [49] K. Yoshida, K.H.C. Gowers, H. Lee-Six, D.P. Chandrasekharan, T. Coorens, E.F.
- 764 Maughan, K. Beal, A. Menzies, F.R. Millar, E. Anderson, S.E. Clarke, A.
- 765 Pennycuick, R.M. Thakrar, C.R. Butler, N. Kakiuchi, T. Hirano, R.E. Hynds, M.R.
- 766 Stratton, I. Martincorena, S.M. Janes, P.J. Campbell, Tobacco smoking and
- 768 (2020) 266–272. https://doi.org/10.1038/s41586-020-1961-1.<br>769 [50] T.G. Paulson, P.C. Galipeau, K.M. Oman, C.A. Sanchez, M.K. Kuhner
- 769 [50] T.G. Paulson, P.C. Galipeau, K.M. Oman, C.A. Sanchez, M.K. Kuhner, L.P. Smith,<br>770 K. Hadi. M. Shah. K. Arora. I. Shelton. M. Iohnson. A. Corvelo. C.C. Malev. X.
- 769 [50] T.G. Paulson, P.C. Galipeau, K.M. Oman, C.A. Sanchez, M.K. Kuhner, L.P. Smith,
- 770 K. Hadi, M. Shah, K. Arora, J. Shelton, M. Johnson, A. Corvelo, C.C. Maley, X.
- 772 B.J. Reid, X. Li, Somatic whole genome dynamics of precancer in Barrett's<br>773 esophagus reveals features associated with disease progression, Nat.
- 772 B.J. Reid, X. Li, Somatic whole genome dynamics of precancer in Barrett's

773 esophagus reveals features associated with disease progression, Nat.

- 775 [51] I. Martincorena, J.C. Fowler, A. Wabik, A.R.J. Lawson, F. Abascal, M.W.J. Hall,<br>776 A. Cagan. K. Murai. K. Mahbubani. M.R. Stratton. R.C. Fitzgerald. P.A.
- 775 [51] I. Martincorena, J.C. Fowler, A. Wabik, A.R.J. Lawson, F. Abascal, M.W.J. Hall,
- 776 A. Cagan, K. Murai, K. Mahbubani, M.R. Stratton, R.C. Fitzgerald, P.A.
- 778 colonize the human esophagus with age, Science. 362 (2018) 911–917.<br>779 https://doi.org/10.1126/science.aau3879.
- 779 https://doi.org/10.1126/science.aau3879.<br>780 [52] A.R.J. Lawson, F. Abascal, T.H.H. Coorens, Y.
- 780 [52] A.R.J. Lawson, F. Abascal, T.H.H. Coorens, Y. Hooks, L. O'Neill, C. Latimer, K.<br>781 Raine. M.A. Sanders. A.Y. Warren. K.T.A. Mahbubani. B. Bareham. T.M. Butle
- 780 [52] A.R.J. Lawson, F. Abascal, T.H.H. Coorens, Y. Hooks, L. O'Neill, C. Latimer, K.
- 781 Raine, M.A. Sanders, A.Y. Warren, K.T.A. Mahbubani, B. Bareham, T.M. Butler,
- 782 L.M.R. Harvey, A. Cagan, A. Menzies, L. Moore, A.J. Colquhoun, W. Turner, B.
- Zumalave, J. Nangalia, J.M.C. Tubío, M. Gerstung, K. Saeb-Parsy, M.R. Stratton, 784 Zumalave, J. Nangalia, J.M.C. Tubío, M. Gerstung, K. Saeb-Parsy, M.R. Stratton,

- 
- 9785 P.J. Campbell, T.J. Mitchell, I. Martincorena, Extensive heterogeneity in<br>186 somatic mutation and selection in the human bladder, Science. 370 (2020)<br>187 15–82. https://doi.org/10.1126/science.aba8347.
- 787 75–82. https://doi.org/10.1126/science.aba8347.<br>788 [53] C.H. Nam, J. Youk, J.Y. Kim, J. Lim, J.W. Park, S.A. Oh,
- 788 [53] C.H. Nam, J. Youk, J.Y. Kim, J. Lim, J.W. Park, S.A. Oh, H.J. Lee, J.W. Park, H.<br>789 Won. Y. Lee. S.Y. Jeong. D.S. Lee. J.W. Oh. J. Han. J. Lee. H.W. Kwon. M.J. Kir
- 788 [53] C.H. Nam, J. Youk, J.Y. Kim, J. Lim, J.W. Park, S.A. Oh, H.J. Lee, J.W. Park, H.
- 790 Y.S. Ju, Widespread somatic L1 retrotransposition in normal colorectal<br>791 epithelium. Nature 617 (2023) 540–547. https://doi.org/10.1038/s41.
- 791 epithelium, Nature 617 (2023) 540–547. https://doi.org/10.1038/s41586-<br>792 023-06046-z.
- $792$  023-06046-z.<br> $793$  541 M Shedonas K 7an M Zakadi H Masonas Manafori H Parkori.
- 793 [54] M. Shademan, K. Zare, M. Zahedi, H. Mosannen Mozaffari, H. Bagheri<br>794 Hosseini, K. Ghaffarzadegan, L. Goshayeshi, H. Dehghani, Promoter
- 793 [54] M. Shademan, K. Zare, M. Zahedi, H. Mosannen Mozaffari, H. Bagheri
- 794 Hosseini, K. Ghaffarzadegan, L. Goshayeshi, H. Dehghani, Promoter
- 796 adenomas and adenocarcinomas, Cancer Cell Int. 20 (2020) 1–16.<br>797 https://doi.org/10.1186/S12935-020-01511-5.
- 797 https://doi.org/10.1186/S12935-020-01511-5.<br>798 798<br>798<br>798
- 
- 798

Figure 1. Retrol<br>801 Figure 1. Retrol<br>802 Scatterplot and cor<br>804 transductions mea<br>805 sequencing covera;<br>806 total of 2,480 rand<br>807 of RetroTest with<br>808 generated GRC37/<br>1809 transductions at di<br>810 of L1 integrations, S02 Scatterplot and correlation between L1 activation and orphan transductions (TD2)<br>in the International Consortium of PanCancer (PCAWG) data. The number of L1 3'<br>transductions measured 1.1 activation. C. Performance of 802 Scatterplot and correlation between L1 activation and orphan transductions (TD2)<br>803 in the International Consortium of PanCancer (PCAWG) data. The number of L1 3'<br>804 transductions measured L1 activation. **C.** Perform 804 transductions measured L1 activation. **C**. Performance of RetroTest for different<br>805 sequencing coverages using an artificially generated GRC37/hg19 genome with a 805 sequencing coverages using an artificially generated GRC37/hg19 genome with a<br>
806 translation of 2.480 randomly distributed L1 transductions at 50% VAF. D. Performance<br>
807 of RetroTest with respect to the VAF of L1 806 total of 2,480 randomly distributed L1 transductions at 50% VAF. **D.** Performance<br>807 of RetroTest with respect to the VAF of L1 integrations, using the artificially 808 generated GRC37/hg19 genome with a total of 2,480 randomly distributed L1<br>809 transductions at different VAFs. **E.** Performance of TraFiC with respect of the VAF 809 transductions at different VAFs. **E.** Performance of TraFiC with respect of the VAF<br>810 of L1 integrations, using the artificially generated GRC37/hg19 genome with a 811 total of 2,480 randomly distributed L1 transductions at different VAFs. **F.** Venn<br>812 diagram of the number of L1 insertions detected by RetroTest and TraFiC in the 813 artificial genome with a VAF of 50% for L1 insertions.<br>814

807 of RetroTest with respect to the VAF of L1 integrations, using the artificially<br>generated GRC37/hg19 genome with a total of 2,480 randomly distributed L1<br>transductions at different VAFs. E. Performance of TraFiC with r 810 of 1.1 integrations, using the artificially generated  $GRC37/hg19$  genome with a total of 2,480 randomly distributed L1 transductions at different VAFs. F. Venn<br>diagram of the number of L1 insertions detected by RetroTe 812 diagram of the number of L1 insertions detected by RetroTest and TraFiC in the artificial genome with a VAF of 50% for L1 insertions.<br>814<br>815 **Figure 2. L1 activation measured by RetroTest in the HNSCC cohort** (n=96). 813 artificial genome with a VAF of 50% for L1 insertions. 815<br>816 916 Quantification of L1 activation in HNSCC tumors as the number of orphan<br>817 transduction detected by RetroTest **B**. Boxplot of L1 activation with respect to<br>818 early (T1-T2) and advanced (T3-T4) TNM stages. Differenti 916 Quantification of L1 activation in HNSCC tumors as the number of orphan<br>817 transduction detected by RetroTest. **B.** Boxplot of L1 activation with respect to<br>818 early (T1-T2) and advanced (T3-T4) TNM stages. early (T1-T2) and advanced (T3-T4) TNM stages. Differential activation p-value<br>
819 was derived by the Wilcoxon test. To correct coverage-related bias, L1 activation<br>
820 was calculated as the number of TD2 divided by its 819 was derived by the Wilcoxon test. To correct coverage-related bias, L1 activation<br>820 was calculated as the number of TD2 divided by its median coverage. **C.** Boxplot of 820 was calculated as the number of TD2 divided by its median coverage. **C**. Boxplot of<br>821 L1 activation with respect to smoking status. Differential activation p-value was 821 L1 activation with respect to smoking status. Differential activation p-value was<br>822 derived by the Wilcoxon test. To correct coverage-related bias, L1 activation was<br>823 calculated as the number of TD2 divided by its 822 derived by the Wilcoxon test. To correct coverage-related bias, L1 activation was<br>823 calculated as the number of TD2 divided by its median coverage. **D.** Kaplan-Meier 823 dealculated as the number of TD2 divided by its median coverage. **D.** Kaplan-Meier<br>824 derves for overall survival with respect to L1 activation rate at T1 stage. Patients 824 curves for overall survival with respect to L1 activation rate at T1 stage. Patients<br>31  $\begin{array}{c} \hbox{131} \ \hbox{232} \ \hbox{231} \ \hbox{232} \ \hbox{233} \ \hbox{234} \ \hbox{235} \ \hbox{237} \ \hbox{238} \ \hbox{238} \ \hbox{239} \ \hbox{23$ 

were grouped into high (above the median) and low (below the median) L1<br>826 activation rate. Log-rank test was used to calculate the p-value. To correct<br>827 coverage-related bias, L1 activation was calculated as the number 827 coverage-related bias, L1 activation was calculated as the number of TD2 divided<br>828 by its median coverage. **E**. Oncoplot showing the genes affected by L1 insertions 828 by its median coverage. **E**. Oncoplot showing the genes affected by L1 insertions<br>829 and their original source elements. A total of 27 patients presented genes affected 830 by L1 insertions from 46 different source elements.<br>831  $831$ <br> $831$ <br> $832$  Eiguns 2 Characterization of the mutational m

928 by IL insertions from 46 different source elements. A total of 27 patents presented genes affected<br>1830 by IL insertions from 46 different source elements.<br>1832 Figure 3. Characterization of the mutational profile of H 832<br>833 **EXECTS THE SECTS THE SECTS THE SECTS THE MUSCULTER CONDUCT SAMPLE 383**<br> **B334 FINSCC** patients. The type of mutation in each gene and the L1 activation (number of L1 insertions in each patient) is shown. **B.** Boxplot of L 834 HNSCC patients. The type of mutation in each gene and the L1 activation (number of L1 insertions in each patient) is shown. B. Boxplot of L1 activation with respect to TP53 mutation or wild-type status. To correct cove 834 HNSCC patients. The type of mutation in each gene and the L1 activation (number<br>835 of L1 insertions in each patient) is shown. **B.** Boxplot of L1 activation with respect<br>836 to TP53 mutation or wild-type status. To co 836 to TP53 mutation or wild-type status. To correct coverage-related bias, L1<br>837 activation was calculated as the number of TD2 divided by its median coverage.<br>838 Differential activation p-value was derived by the Wilco 837 – activation was calculated as the number of TD2 divided by its median coverage.<br>838 – Differential activation p-value was derived by the Wilcoxon test. **C.** Barplot of the 838 Differential activation p-value was derived by the Wilcoxon test. **C**. Barplot of the<br>839 Pathway enrichment analysis based on the 918 genes somatically mutated genes. Pathway enrichment analysis based on the 918 genes somatically mutated genes.<br>
Brichment p-values were calculated with the Fisher exact test. **D**. Barplot of the<br>
derived presential p-values was derived by the Wilcoxon tes 840 Enrichment p-values were calculated with the Fisher exact test. **D**. Barplot of the<br>841 transcription factor binding enrichment analysis based on the 918 genes 842 somatically mutated genes. Enrichment p-values were calculated with the Fisher<br>843 exact test.  $843$  exact test.  $843$ 844<br>844<br>945 **Eisus 4** 

841 transcription factor binding enrichment analysis based on the 918 genes<br>842 somatically mutated genes. Enrichment p-values were calculated with the Fisher<br>843 exact test.<br>844 **Figure 4. Evaluation of L1 activation in n** 844<br>845<br>846 Example 1. Example 1. Evaluation of the field cancerization process. **B.** Number of L1 active elements in normal adjacent tissue of HNSCC patients (n=9), compared to L1 activation in paired tumor tissue and PBMCs as germl example active elements in normal adjacent tissue of HNSCC patients (n=9), compared to L1 activation in paired tumor tissue and PBMCs as germline control from the same patients. 847 active elements in normal adjacent tissue of HNSCC patients (n=9), compared to L1<br>848 activation in paired tumor tissue and PBMCs as germline control from the same<br>849 patients. 849 activation in pairce tumor tissue and PBMCs as germine control from the same<br>849 actions. 849 patients.<br>B









### **FIGURES**

### Figure 1.



- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 

### Figure 2.



901<br>902

Figure 3.



- 915<br>916
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 



- 
- 
- 
- 
- 
- 
- 





Sample n=27

- 
- 
- 
- 
- 
- 
- 
- 
- 
- 











